Functional analysis across model systems implicates ribosomal proteins in

growth and proliferation defects associated with hypoplastic left heart syndrome

Tanja Nielsen[1,4,*], Anaïs Kervadec[1,*], Jeanne L. Theis[2,*], Maria A. Missinato[1], James

Marchant[1] , Michaela Lynott[1], Aashna Lamba[1], Xin-Xin I. Zeng[1], Marie Berenguer[1],

Stanley M. Walls[1], Analyne Schroeder[1], Katja Birker[1], Greg Duester[1], Paul Grossfeld[3],

Timothy J. Nelson[2], Timothy M. Olson[2,], Karen Ocorr[1], Rolf Bodmer[1,#], Georg Vogler[1,#],

Alexandre R. Colas[1,#]

[1]Development, Aging and Regeneration Program, Center for Genetic Disorders and

Aging Research, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA,

USA.

[2]Cardiovascular Genetics Research, Mayo Clinic, Rochester, MN, USA.

[3]University of California San Diego, Rady Children's Hospital, San Diego, CA, USA.

[4]Department of Biochemistry, Chemistry and Pharmacy, Freie Universität Berlin, Berlin,

Germany

* These authors contributed equally

[#] Co-corresponding authors

Keywords: Congenital heart disease, HLHS, whole genome sequencing, rare variant

filtering, cardiogenesis, *Drosophila*, iPSC, zebrafish, *RPS15A*, *TP53*, *yorkie*,

tinman/NKX2-5, Dorsocross/TBX5, pannier/GATA6.

Abstract

Hypoplastic left heart syndrome (HLHS) is the most lethal congenital heart
disease (CHD). The pathogenesis of HLHS is poorly understood, and due to the likely
oligogenic complexity of the disease, definitive HLHS-causing genes have not yet been
identified. Postulating impaired cardiomyocyte proliferation as a likely important
contributing mechanism to HLHS pathogenesis, and we conducted a genome-wide
siRNA screen to identify genes affecting proliferation of human iPSC-derived
cardiomyocytes (hPSC-CMs). This yielded ribosomal protein (RP) genes as the most
prominent class of effectors of CM proliferation. In parallel, whole genome sequencing
and rare variant filtering of a cohort of 25 HLHS proband-parent trios with poor clinical
outcome revealed enrichment of rare variants of RP genes. In addition, in a familial
CHD case we identified a rare, predicted-damaging promoter variant affecting *RPS15A*
that was shared between the HLHS proband and a distant relative with CHD. Functional
testing with an integrated multi-model system approach reinforced the idea that RP
genes are major regulators of cardiac growth and proliferation, thus potentially
contributing to the hypoplastic phenotype observed in HLHS patients. Cardiac
knockdown (KD) of RP genes with promoter or coding variants (*RPS15A, RPS17,*
RPL26L1, RPL39, RPS15) reduced proliferation in generic hPSC-CMs and caused
malformed hearts, heart-loss or even lethality in *Drosophila*. In zebrafish, diminished
rps15a function caused reduced CM numbers, heart looping defects, or weakened
contractility, while reduced *rps17* or *rpl39* function caused reduced ventricular size or
systolic atrial dysfunction of the atrium, respectively. Importantly, genetic interactions
between *RPS15A* and core cardiac transcription factors *TBX5* in CMs, *Drosocross,*
pannier and *tinman* in flies, and *tbx5* and *nkx2-7* (*nkx2-5* paralog) in fish, support a
specific role for RP genes in heart development. Furthermore, *RPS15A* KD-induced
heart/CM proliferation defects were significantly attenuated by *p53* KD in both hPSC-
CMs and zebrafish, and by Hippo activation (*YAP/yorkie* overexpression) in developing
fly hearts. Based on these findings, we conclude that RP genes play novel critical roles
in cardiogenesis and constitute an emerging class of gene candidates likely involved in
HLHS and other CHDs*.*

Introduction

Hypoplastic left heart syndrome (HLHS) accounts for 2-3% of all cases of congenital heart disease (CHD) [1, 2] and is characterized by underdevelopment of the left ventricle, mitral and aortic valves, and aortic arch [3]. HLHS has a recognized genetic component based on its familial association with left-sided obstructive congenital heart diseases [4-6]. However, segregation analyses in multiplex HLHS-CHD families [6] and genome-wide association studies (GWAS) of large cohorts [5] have lacked sufficient power to conclusively identify candidate HLHS-susceptibility genes with small to moderate effect sizes. Defects in a small number of genes involved in cardiogenesis, such as *NOTCH1* [7], *NKX2–5* [8], *MYH6* [9], and *GATA4* [8, 10] have been implicated as contributors to HLHS, as well as multiple other CHDs. However, the variety of phenotypic manifestations of HLHS, together with numerous studies linking it to diverse genetic loci [7-9, 11], suggests that HLHS is genetically heterogeneous and has a multigenic etiology [12, 13].

It has also been hypothesized that the underdevelopment of the left ventricular myocardium includes restricted blood flow across the mitral valve and its hemodynamic effect during ventricular growth and development ("no flow – no grow" [14]), as well as endocardial defects [15]. Therefore, HLHS manifestation may be due to a combination of cardiomyocyte autonomous and non-autonomous genetic as well as mechanical effects, all of which likely affect proliferation and differentiation in the developing heart.

In a digenic HLHS mouse model, loss of both Sin3A Associated Protein 130 (*Sap130)* and the protocadherin *Pcdha9* cause decreased CM proliferation resulting in left ventricular (LV) hypoplasia [16]. In addition, LVs from HLHS patients have cardiac damage associated with CM proliferation defects compared to healthy subjects [17]. These studies suggest that intrinsically defective cardiac differentiation and impaired CM proliferation are likely contributing to HLHS-associated heart defects. Further strengthening this hypothesis, we found that HLHS-patient-derived hPSC-CMs exhibited reduced proliferation compared to the parents [18]. There is a need to identify the potentially causative genes, which contribute to those processes described above and to elucidate their role in CHD/HLHS pathogenesis.

To advance CHD gene discovery, we have developed a multi-model systems
platform enabling to both rigorously prioritize candidate genes from whole-genome
sequencing (WGS) based on rare, predicted-damaging variants and their mode of
inheritance, and to functionally characterize gene function in complementary and
genetically tractable model systems: human induced pluripotent stem cells (hPSC), the
fruit fly *Drosophila melanogaster* and zebrafish *Danio rerio*. The genetic basis of cardiac
development, originally uncovered in *Drosophila*, is fundamentally conserved across
species [19-22] and ~80% of human disease genes have fly orthologs [23]. In addition,
the non-redundant fly genome together with the simple structure and function of the fly
heart allow straightforward genotype-phenotype correlations. Zebrafish [24-26], which
has a two-chambered heart and can be easily manipulated using morpholino injections
and CRISPR technologies to affect heart development and function. In addition,
phenotypes can be directly observed in the developing larva for several days post
fertilization [27]. Finally, cardiomyocytes (CMs) differentiated from hPSCs (hPSC-CMs)
enable to identify and quantify cellular phenotypes associated with human diseases,
including HLHS [7, 28-30] and are amenable to large scale functional screens [31, 32],
thereby enabling to serve both as a discovery and validation platform. This integrated
approach allows to rapidly identify novel HLHS-associated gene candidates and to
characterize their ability to regulate developmental processes associated with disease
(e.g., hypoplasia) [18].

Defective CM proliferation is likely a hallmark of HLHS [16-18], thus to uncover
novel regulators of human CM proliferation with potential links to HLHS, we performed a
whole genome siRNA screen (18,055 genes) using an EdU assay in hPSC-CMs, and
identified ribosomal proteins (RPs) as the major class of genes controlling CM
proliferation. In parallel, whole genome sequencing (WGS) of 25 poor-outcome HLHS
proband-parent trios followed by unbiased variant filtering, revealed an enrichment for
rare, predicted-damaging variants in RP genes. Moreover, analysis of a high-value
family (75H) comprised of a HLHS proband, his phenotypically normal parents, and a
fifth degree relative born with left-sided CHD led to the identification of a predicted-
damaging variant in RP protein gene *RPS15A* that segregated with disease. Consistent
with a central role for RPs in the regulation of heart development, heart-specific knock-

down (KD) of HLHS-associated RPs in *Drosophila* caused severe phenotypes, including

near complete heart-loss and lethality. Similarly, in zebrafish, *rps15a* CRISPR mutants

and morphants had greatly reduced heart size and CM number, looping defects and

diminished contractility. In this context, a multi-model system evaluation (hPSC-CMs,

flies and zebrafish) of RP function show their important role on heart growth and

differentiation and CM proliferation by modulating the p53, Myc and Hippo pathways.

Moreover, we find evidence that RPs may regulate heart development and CM

proliferation in a cardiac-specific manner by synergistically interacting with core cardiac

transcription factors such as T-box, Nkx and Gata factors. In sum, here we show that

RP genes are potent regulators of CM proliferation and cardiac growth and

differentiation, consistent with a potentially critical role in the hypoplastic phenotype of

HLHS. We suggest that RP genes are an emerging class of novel genetic effectors in

HLHS/CHD.

Results

Whole genome siRNA screen identifies ribosomal proteins as central regulators of cardiomyocyte proliferation

Based on previous and our recent data [16-18], impaired cardiomyocyte (CM) proliferation is emerging as an important mechanism in HLHS pathogenesis. Thus, to comprehensively map the human genome for novel regulators of CM proliferation, we screened a library of 18,055 siRNAs for their ability to modulate proliferation in human iPSC-derived CMs (hPSC-CMs). To assess CM proliferation, we used a dual read-out and quantified both DNA synthesis using EdU incorporation [31], and total number of CMs, 3 days after treatment (**Figure 1A-C**). Briefly, siRNAs were transfected into 25-day old hPSC-CMs [29, 33]. After 2 days, EdU was added to the wells for 24 hours. On day 3, cells were fixed and co-stained for sarcomeric protein alpha-Actinin (ACTN2), EdU, and DAPI. Next, the number of EdU/alpha-Actinin double-positive cells, and the total number of CMs were determined using a commercially available high-throughput image analysis software (MetaXpress, Molecular Devices)[31]. Note that alpha-Actinin-, EdU+ cells which typically express fibroblast markers (i.e POSTN)[34], were excluded from this analysis, to focus on CM biology only. In total, we found 153 siRNAs that decreased proliferation (< 0.5-fold EdU incorporation) and number of CMs (<0.8-fold), and 162 siRNAs that increased EdU (>1.2-fold) and CM number (>1.1-fold; **Figure 1B, C and Supplemental Table 1**). Consistent with previous studies [35, 36], KD of cell cycle checkpoint agonist, CHEK1 and MDM2, the negative regulator of TP53, both were among top hits that reduced CM proliferation. As expected, we identified TP53 and CDKN1A among the genes that significantly increased CM cell number upon KD (**Figure 1B, C**). Next, to gain insight into the molecular pathways regulating proliferation in hPSC-CMs, we performed Gene Ontology (GO) term analysis of hits decreasing EdU incorporation or CM numbers and found an enrichment for genes associated with "translation/ribosome" and p53 signaling as top hits (**Figure 1D, E**). Consistent with these observations, we had previously found that the p53 pathway is dysregulated in hPSCs differentiated from a HLHS family trio [18]. Remarkably, the most represented gene family are ribosomal proteins (RPs), KD of which caused consistently the

strongest inhibition of cell proliferation (**Figure 1B**). Next, since, the primary screen was

performed as a single data point, we next sought to validate these findings by re-testing

all 80 RP genes for function [37] using a distinct set of siRNAs in biological

quadruplicate conditions. Remarkably and consistent with the primary screen, KD of

59/80 RPs significantly reduced proliferation as compared to siControl (p<0.05;

Supplemental Figure 1A, B). Collectively, these findings indicate that RP function is

essential for hPSC-CM proliferation and thus, suggest that RPs might represent a new

class of regulators of ventricular growth during embryonic development.

Enrichment of RP gene variants in an HLHS patient cohort with poor clinical

outcome

To identify candidate genes involved in HLHS pathogenesis, we performed whole

genome sequencing (WGS), variant filtering, and enrichment analysis (see also [18],

and Methods: WGS and bioinformatic strategies) in a cohort of 25 HLHS patient-parent

trios with poor clinical outcome defined as either prenatal – restrictive atrial septal defect

(n=2); postnatal – reduced right ventricular ejection fraction following stage II or III

surgical palliation (n=19); protein-losing enteropathy (n=2); or cardiac

transplantation/failed surgical palliation (n=2). The 25 probands were comprised of 18

males and 7 females, 24 of whom were of white ancestry. The HLHS phenotype with

respect to valve morphology (mitral atresia, MA; mitral stenosis, MS; aortic atresia, AA;

aortic stenosis, AS) was: MA/AA in 10, MS/AS in 9, MA/AA in 4, MA/AS in 1 and

unknown in 1. CHD in the parents was excluded by echocardiography in all but two

families, in which a bicuspid aortic valve was present in the mother. Genomic

sequences were filtered for uncommon (MAF < 1%) *de novo* and recessive variants in

coding and regulatory regions of genes expressed in the developing heart and predicted

to alter protein structure or expression, yielding 292 unique HLHS candidate genes that

primarily fit a recessive mode of inheritance (Figure **2A and Supplemental Table 2**). To

determine whether certain gene networks were over-represented among these variants,

we used two online bioinformatics tools (STRING and PANTHER [38, 39]). After

applying Fisher's exact test and false discovery rate corrections, RPs were the most

enriched class of proteins when compared to the reference proteome, which includes

data annotated by protein class (5.24-fold, p=0.0028), and cellular component (7.27-
fold, p=0.011). In total, 14 variants found in 9 RP genes among 6 HLHS probands were
identified, most fitting a recessive inheritance disease model (**Supplemental Table 3**).
These RP variants encompass mutations in upstream promoter regions that potentially
affect transcription factor binding sites, as well as non-synonymous substitutions inside
the protein coding regions.

Next, all 292 prioritized candidate genes were systematically evaluated for
effects on the proliferation of hPSC-CMs *in vitro* and for cardiac differentiation of fly
hearts *in vivo.* Again, loss of RP function (*RPL39, RPL26L1, RPS15, RPS17, RSPS28*)
caused the most severe phenotypes on proliferation in hPSC-CMs (**Figure 2B**), which
was consistent with our genome-wide proliferation screen (see **Figure 1B**). In the fly,
KD of RPs in the cardiac lineage and throughout embryonic development was achieved
using a *Hand$^{4.2}$*-Gal4 driver (see [40] and methods), and led to partial or complete heart
loss (*RpL26, RpL36A, RpL3*) or caused lethality (*RpS17, RpL39, RpS15, RpL26,*
RpL36A) (Figure **2C**). Also, KD of *RpL10* gave rise to severely constricted hearts, while
KD of *RpS28b* caused inflow tract defects (**Figure 2C**). Finally, functional testing of RPs
in zebrafish embryos revealed that KD of *rpl39* leads to reduced ventricle size, whereas
rps17 CRISPR mutants exhibit systolic dysfunction (**Figure 2D, E**). In sum, our patient
centric approach (cohort of 25 probands) identifies RPs as the most enriched gene
category affected by HLHS-associated variants (STRING, PANTHER analysis). In this
context, systematic testing in multi-model systems (fly, zebrafish, hPSC-CMs) identifies
RPs as most potent regulators of cardiac differentiation, proliferation and contractility
among HLHS-associated genes. Collectively, these findings highlight that RPs regulate
critical steps of cardiogenesis that are also found to be defective in HLHS probands [41,
42], and thus suggest a potential link between RP biology and HLHS phenotypic
etiology.

RPS15A variant associated with HLHS in familial CHD

To further establish a phenotypic link between RP function and HLHs associated
phenotypes, we selected a rare familial CHD case (75H) (**Supplemental Figure 2A**),

that is comprised of a young teenager with HLHS (MS/AS) and normal ventricular
function following Fontan operation, his phenotypically normal parents, and a 5th degree
female relative born with left-sided CHD (bicuspid aortic valve and coarctation of the
aorta). Based on these observations, we hypothesized the presence of a heterozygous
driver variant exhibiting incomplete penetrance and variable expression. To investigate
further, we filtered whole-genome sequencing (WGS) data for rare, predicted-damaging
variants in coding and regulatory regions. This analysis identified six prioritized variants
(**Supplemental Table 4**), including one located in the *RPS15A* gene locus, shared by
the HLHS proband, the unaffected mother, and the proband's fifth-degree relative with
congenital heart disease (CHD).

We next investigated whether family members carrying these variants (the
mother and proband) exhibit defects in cardiomyocyte (CM) proliferation compared to
the father. Notably, analysis of EdU incorporation in CMs from the parent-proband trio
revealed significantly reduced proliferation in both the proband and mother compared to
the father. However, the proband displayed a markedly more severe phenotype than the
mother (**Figure 3 A,B**). Interestingly, this reduction in proliferation appeared to be
specific to cardiomyocytes (CMs), as EdU incorporation in the non-CM cell population
showed no significant differences among the family members (**Supplemental Fig. 2B**).
Collectively, these findings suggest a phenotypic association between the presence of
the variants and impaired CM proliferation.

Finally, to determine the potential relative contribution of the six genes harboring
rare and damaging variants in the regulation of CM proliferation, we performed
functional KD experiments in hPSC-CMs *in vitro*. Remarkably, while KD of 5 of the other
prioritized genes from the 75H family also resulted in moderate reduced CM
proliferation, RPS15A KD produced the most pronounced effect, with over an 85%
reduction in proliferation, emerging as the top candidate (**Figure 3C, D**). Together,
these findings indicate that RPS15A plays a critical role in regulating cardiomyocyte
(CM) proliferation in human pluripotent stem cells (hPSCs) and may influence heart
developmental processes that are disrupted in HLHS.

RPS15A KD in *Drosophila* and zebrafish causes severe cardiac proliferation and differentiation defects

To characterize the role of *RPS15A* during heart development, we first induced a heart-specific KD of *RpS15Aa* in flies (see methods), which caused a partial or complete loss of the heart (**Figure 3E,F**). Note that this phenotype is consistent with our results above and a previous study involving another RP gene (*RPL13*) [43].

Next, to evaluate the role of *RP* genes during heart development, we knocked-out *rps15a* in zebrafish (*Danio rerio*) using CRISPR [24-26]. We examined F_0 larva at 72 hpf (hours post fertilization) using high speed digital imaging (SOHA [44], see also methods) and confocal microscopy to monitor heart size and cardiomyocyte numbers respectively. Remarkably, *rps15a* mutants hearts were smaller in size (**Supplemental Fig. 2C,D**), with reduced CM numbers (**Figure 3G,H**). Interestingly, CM numbers were predominantly reduced in the ventricle compared to the atrium (**Figure 3G,H)**. We observed similar effects in response to injection of a *rps15a* morpholino (MO) compared to uninjected larva [45, 46] (**Supplemental Figure 2 C,D**). In this context, we also noted that the overall body plan and morphology of *rps15a* CRISPR mutants or morphants were largely unaffected, except for a mild pericardial edema, a possible indicator of heart dysfunction (**Figure 3H**) [47]. Collectively, these data support the hypothesis that *RPS15A* is required for CM proliferation and heart morphogenesis (hPSC-CMs, fly and zebrafish), thus suggesting a potential role for RPs as genetic drivers of hypoplasticity observed in HLHS or defects in other CHDs.

Ribosomal proteins control CM cell cycle by regulating TP53 pathway activity

To investigate how RPs regulate cell cycle activity in hPSC-CMs, we performed RNA-seq upon KD of *RPS15A* and *RPL39*, which belong to the small and the large ribosomal subunits that harbor predicted-damaging variants in 75H and 151H probands, respectively. Comparison of differential gene expression between *siRPS15A* and *siRPL39* KD revealed that ~53% of genes were commonly dysregulated (**Figure 4A**), indicating the existence of a conserved RP-dependent transcriptional network. Consistent with a central role for RPs in the regulation of proliferation, GO term analysis for differentially expressed genes revealed an enrichment for genes involved in DNA

replication, mitosis and DNA damage response mediated by p53, and included the
downregulation of positive regulators of cell cycle such as *CDK1, CCNA2, AURKA,*
PCNA and the upregulation of cell cycle arrest mediators such as *CDKN1A, BTG2,*
GADD45A (**Figure 4B** and **Supplemental Tables 5,6**). To confirm these findings, we
performed immunostaining for canonical p53 downstream transcriptional target [48],
CDKN1A, and observed that the percentage of CDKN1A+ CMs was increased by ~60%
in response to *RPS15A* KD (**Figure 4C, D**), indicating that RP KD induces cell cycle
arrest *via* the activation of the p53 signaling pathway in hPSC-CMs.

Next, to evaluate if the reduction in proliferation caused by RP KD is mediated by
the p53 signaling pathway in CMs, we co-KD *TP53* or *CDKN1A* along with *RPS15A,*
and observed a significant rescue of CM proliferation by EdU incorporation and CM
number in comparison to RPS15A KD (**Figure 4E, F** and **Supplemental Figure 4A, B**).

Next, we tested if RP-mediated defects in zebrafish can also be rescued by
inhibition of p53. To this aim, we used morpholinos to co-KD *p53* with *rps15a* [49] and
examined larval hearts at 72 hpf. *p53* MO-mediated KD on its own had little effect on
heart function but partially reversed the *rps15a* MO-mediated reduction in heart size and
cardiomyocyte numbers (**Figure 4G, H**). Moreover, bradycardia, heart looping and
reduced contractility phenotypes of *rps15a* morphants were also rescued by co-KD of
p53 (**Supplemental Figure 4C, D)**. Collectively, these observations support our
hypothesis that RPs control cardiac development, including heart size and function, *via*
a p53 pathway-mediated regulation of CM proliferation.

Heart loss in *Drosophila* by RpS15Aa KD is partially rescued by Hippo pathway
activation

The fly heart develops similarly to the vertebrate heart at early stages [20] and a
link between RPs and cell cycle-regulating pathways, such as p53 and Hippo pathways
[50], has been proposed to be conserved between mammals and flies [51]. To test
whether p53 has a function in fly heart development similar to hPSC-CMs and
zebrafish, we performed cardiac co-KD of *RpS15Aa* and *p53* and examined heart
structure and function. Co-KD did not rescue the cardiac defects of *RpS15Aa* KD

suggesting that *p53* has a different role in flies, as compared to vertebrates, as has
been reported previously [52].

In vertebrates, TP53 is known to act through the negative regulation of the Hippo
pathway [53]. In this context, YAP, a downstream effector of Hippo, has been shown to
promote CM proliferation in the mouse heart [54]. We therefore tested if YAP/yorkie can
substitute the function of p53 in the fly heart and found that overexpressing the Hippo
pathway gene *yorkie* (*yki*), the fly ortholog of YAP, in the developing heart considerably
restored *RpS15Aa* KD-induced heart loss in *Drosophila* (**Figure 5A',B**). We also
observe formation of adult ostial structures, which indicates that the larval heart
underwent partial remodeling to an adult heart during metamorphosis. Further, we found
that *yki*-mediated rescue depends on the transcriptional co-factor encoded by *scalloped*
(*sd*, *Drosophila TEAD1/2/3/4*), since upon *sd* KD, *yki* OE can no longer rescue the
RpS15Aa KD-induced heart loss (**Figure 5A", B**). Moreover, KD of *sd* in an *RpS15Aa*
KD background (without *yki* OE) worsens the *RpS15Aa* KD phenotype (**Figure 5A", B**).

RPS15A* genetically interacts with cardiac transcription factors *nkx2.7/tinman,
and TBX5/*tbx5a/Dorsocross, nkx2.7/tinman,* and *Gata4,5,6/pannier* in model
systems

The profound importance of RPs for cell growth and proliferation in most cell
types ([55] and **Supplemental Figure 1**), raises the question of how tissue specific
phenotypes such as those observed in HLHS can arise from the defective function of
ubiquitously expressed genes. To address this apparent paradox, we hypothesized that
RPs might functionally interact with tissue-specific proteins such as cardiac transcription
factors (cTFs), to control CM proliferation. Analysis of the impact of cTFs alone on
hPSC-CM proliferation from our whole genome screen, revealed that KD of most cTFs
did not cause major proliferation defects (except for e.g., *HES4* and *HOPX*; **Figure 6A**).
Among the cTFs, TBX5 is specifically expressed in the left ventricle at stages of intense
CM proliferation [56] and thus we next asked if *TBX5* could functionally interact with
RPs. Remarkably, while hPSC-CM proliferation was not affected by increasing doses of
siTBX5 (0-2nM), increasing si*TBX5* dosage in siRP backgrounds led to proportional

decrease in EdU incorporation (Two-way ANOVA; **Figure 6B and Supplemental**
Figure 5A,B), thereby indicating that *RPs* and *TBX5* genetically interact to regulate
proliferation in hPSC-CMs.

Conservation of genetic interactions between human and fly cardiac transcription
factors and constitutive genes have been identified before [57]. We therefore specifically
tested for genetic interaction between *RpS15Aa* and the cardiac TFs *tinman/NKX2-5,*
pannier/GATA4/5/6 and *Dorsocross/TBX5* in adult *Drosophila* hearts*.* A heterozygous
deficiency covering *RpS15Aa* causes moderate dilation of hearts compared to controls
(**Supplemental Figure 5C)**. However, when *RpS15Aa* was placed *in trans* to loss of
function alleles of cardiac TFs *tinman, pannier* or *Dorsocross1/2/3*, these hearts
exhibited significantly deformed hearts, which is only rarely observed in the single
heterozygotes (Figure **5C, D**). In addition, *RpS15Aa* heterozygous flies showed a
prolonged heart period when combined with a *tinman* or *pannier* heterozygous
mutations (**Supplemental Figure 5C**).

Next, we tested whether similar genetic interactions are conserved in zebrafish.
Zebrafish expresses the NKX2-5 ortholog *nkx2.7* in the heart and functional studies
have shown that both *nkx2.5* and *nkx2.7* play critical roles in cardiac development [58].
To determine whether *rps15a* and *nkx2.7 or tbx5a* genetically interact in zebrafish, we
injected low doses of *rps15a* [45] MO, in combination with *nkx2.7* [59] or *tbx5a* MO.
nkx2.7 MO alone had little effect on heart size, cross-sectional area, or contractility,
whereas double morphants exhibited cardiac dysfunction, with contraction virtually
abolished in some animals (**Supplemental Figure 5D**). Furthermore, we observed a
significant prolongation of the heart period in double morphants (*rps15a + nkx2.7* or
rps15a + tbx5a) in comparison to each MO alone (Two-way ANOVA; **Supplemental**
Figure 5D, E) consistent with the effects observed in *Drosophila*. Together, these
results highlight the existence of evolutionarily conserved (fly, zebrafish and hPSC-
CMs) genetic interactions between RPs and cardiac TFs genes in the regulation of
cardiogenesis. These data also illustrate how the activity of ubiquitously expressed
genes such as RPs, can be modulated by cell type-specific genes, like cardiac TFs, to
achieve tissue-specific outcomes.

RP-regulated HLHS-associated genes control proliferation in a CM-specific manner

Previous studies and this work show that reduced RP function can lead to tissue-specific developmental defects, that in turn can be rescued by loss of p53 [60, 61]. While these findings highlight a downstream role for p53 in the development of RP-dependent phenotypes, they also imply that RPs can regulate cell cycle and/or p53 activity in a tissue-specific manner. Thus, to delineate how RPs might control proliferation in a CM-specific manner, we compared differential gene expression profiles upon the two RP KDs in hPSC-CMs and undifferentiated hPSCs (**Figure 7A**). Consistent with our hypothesis, this analysis revealed that RPs regulate the expression of 493 genes in a CM-specific manner (**Supplemental Tables 5-8**), thereby suggesting the existence of a cell type-specific (cardiac) transcriptional response to RP loss of function.

Next, to evaluate whether HLHS-associated genes were part of this lineage-specific transcriptional response, we selected those differentially expressed genes harboring rare and predicted damaging variants in probands from the poor outcome cohort and 75H family (**Supplemental Tables 2, 4**). Remarkably, this prioritization strategy identified 12 genes potentially associated with HLHS (**Supplemental Table 9**), 6 of which were found to also regulate cell cycle activity in hPSC-CMs (**Figure 7B, C**). Thus, collectively this approach led us to identify an RP-dependent and cardiac-specific HLHS-associated gene network that supports CM proliferation *via* the upregulation of *EWSR1, MDC1, PKMYT1* and *KIF1C,* and downregulation of *FAT4* and *EPHA4* (**Figure 7D, E**).

To further explore if RP-regulated HLHS-associated genes control proliferation in a cell type-specific manner, we asked if *EWSR1* KD*,* which elicited the strongest proliferation phenotype in hPSC-CMs, could regulate proliferation in non-cardiac cell types such hPSCs. In contrast to hPSC-CMs, siEWSR1 did not affect the number of OCT4+ cells (**Figure 7F, G**), which suggests that EWSR1 is able to regulate proliferation CM-specifically. EWSR1 is an RNA/DNA binding protein that regulates

transcription and RNA splicing and plays a major role as oncogenic driver when fused to
ETS transcription factors [62]. In a next step, we tested if EWSR1 regulates CM
proliferation by modulating the p53 pathway. Consistent with this hypothesis,
immunostaining for p53 downstream target, CDKN1A, revealed that EWSR1 KD both
increased the percentage of CDKN1A-positive CMs and decreased EdU incorporation
as compared to siControl (**Figure 7H-J**). Consistent with these observations, *RpS15Aa*
deficiency fly line placed *in trans* to loss of function allele for *cabeza* (*caz*), the ortholog
of *EWSR1,* caused prolongation of systolic interval lengths (**Supplemental Figure 5F)**
as compared to controls, suggesting a genetic interaction between these two genes.
Collectively, these results support the conclusion that RPs can modulate proliferation in
a cell type-specific manner, by controlling the expression of downstream effectors (i.e
EWSR1), with a cell type-specific ability to modulate the p53 pathway activity (**Figure
7K and Figure 8**).

Discussion

Implication of ribosomal proteins as genetic modulators in HLHS/CHD
pathogenesis
425
Recent work, including our own, strongly suggest that defective cardiac
differentiation and impaired CM proliferation contribute to HLHS-associated heart
defects [16-18]. In this study, we find that ribosomal proteins are critical for maintaining
CM proliferation, as well as cardiac structure and function in fish and fly heart models.
We show a potential role for RP function in cardiac development and HLHS/CHD
pathogenesis as : (1) RPs are central regulators of cardiomyocyte proliferation, and (2)
RP variants are enriched in a cohort of poor-outcome HLHS patients; (3) a rare
predicted-damaging promoter variant in *RPS15A* was associated with HLHS in familial
CHD (75H); (4) KD of RPs *in vivo* results in cardiac deficiencies in hPSC-CMs,
Drosophila and zebrafish, and (5) induces TP53 signaling and blocks proliferation that
can be alleviated by inhibition of TP53 in the vertebrate models. Interestingly, the
transcriptomic response of a previously reported HLHS proband [18] paralleled these
findings and raises the possibility of an underlying ribosomopathy condition in that

HLHS family. While universally important for cellular growth, an increasing number of
variants in RP genes have been linked to CHD in humans indicating tissue-specific
differences in the penetrance of RP gene mutations. Most notably, ~30% of patients
with Diamond-Blackfan anemia [63], a ribosomopathy characterized by hypo-
proliferative, proapoptotic erythropoiesis, also have CHD. In agreement with another
study [46] *rps15a* KD in fish caused a noticeable reduction in circulating red blood cells.

In addition to RPS15A, *RpL13* was recently identified as a potential candidate
gene involved in CHD from a screen for *de novo* copy number variations (CNVs) in 167
patients with CHD [43]. Furthermore, the Pediatric Cardiac Genomics Consortium
(PCGC) exome dataset of 2871 patients with CHD identified several rare, predicted-
damaging *de novo* variants in RP genes, 2 of which were found in patients with HLHS
[64]. Our finding that RPs genetically interact with core cardiac transcription factors
provides a potential mechanism for the cardiac specificity of RP phenotypes. In this
context, we hypothesize that RP gene variants might play a role as genetic modifiers (or
sensitizers) in the oligogenic pathogenesis of HLHS.

455   Cardiac-specific and RP-dependent regulation of proliferation in the context of
456   HLHS

Defective proliferation in left ventricular CMs is a phenotypic hallmark of HLHS
[16, 17], thereby implying the existence of HLHS-associated mechanisms that regulate
proliferation in a CM-specific specific-manner. In this study, we identified RPs as novel
candidate genetic regulators of hypoplastic phenotypes observed in HLHS, as 1) rare,
predicted damaging variants affecting RP genes are enriched in HLHS probands as
compared to healthy controls, 2) KD of most RPs impairs proliferation in hiPSC-CMs
(59/80 tested) and heart development in flies (6/6 tested), and 3) systemic loss of
rps15A function causes heart-specific hypoplastic phenotypes in zebrafish. However, in
this context, the evaluation of RPs function in multiple cell types revealed that they are
generally required for proliferation (hPSCs, hPSC-CMs and dermal fibroblasts), thus,
indicating that RP loss of function triggers a non-cell type specific cell cycle block.

Thus, an appealing mechanism by which RP function could be invoked in a
spatially restricted manner would involve the regulation of RP expression by cell type-
specific TFs. Consistent with this model, all probands harboring RP variants contain
mutations affecting their promoter regions (**Supplemental Table 1**). Also, several of
these mutations are predicted to disrupt the binding site of previously identified HLHS-
associated TF, ETS1 [15, 65]. Consistent with these observations, a recent study from
the Bruneau lab [66] show that 38 RP genes are downregulated in TBX5-null hiPSC-
CMs and ChIP analysis [67] reveals that a third of these dysregulated RPs (14/38
genes) are bound by TBX5 at their core promoter regions. Thus, we speculate that cell
type specific TFs controlling RP expression represent a promising gene class enabling
to modulate RP-dependent proliferation in a tissue-specific manner.

A second mechanism by which RPs might control proliferation and differentiation
in a CM-specific manner, is based on the hypothesis that CMs may be molecularly more
sensitive to RP loss-of-function than other cell types. Consistent with this model, RP
deficiency predisposes flies, fish and hPSC-CM for interactions with core cardiogenic
TFs, including TBX5/*Doc*, GATA4/*pnr* and NKX2-5/*tin*, the latter being the most cardiac
restricted. (**Fig.** 6). Moreover, our comparative transcriptomics analysis (**Figure 4**)
revealed that RPs regulate gene expression in a CM-specific manner. Among these RP
regulated genes, *EWSR1, MDC1, PKMYT1, KIF1C, FAT4 and EPHA4*, were found to
be mutated in HLHS families and regulate CM proliferation (**Figure 7**). Remarkably,
EWSR1 KD did not affect proliferation in hPSCs, while it strongly reduced EdU
incorporation in hPSC-CMs, thus suggesting that EWSR1 regulates proliferation in a
CM-specific manner. Interestingly, in flies *RpS15Aa* genetically interacts with *cabeza*
(*caz,* the fly ortholog of *EWSR1*). Consistent with our observations, a recent study has
found that overexpression of a fusion Ewsr1-Fli1 protein in mice specifically induces
dilated cardiomyopathy by promoting apoptosis in cardiac myocytes [68]. Similarly,
Fat4, a negative regulator of the hippo pathway, which is upregulated upon RP, KD was
found to specifically regulate heart size via the regulation of CM size and proliferation
[69]. Thus, collectively we propose that RPs represent a central regulatory hub for cell
proliferation and differentiation during embryonic development, which can be modulated

in a cell type-specific manner by tissue-restricted modulators of RP expression and/or
activity.

An RP–MDM2–p53/YAP surveillance network in heart development

Defects in ribosome biogenesis caused, for example, by reduction in RP gene
copy numbers induce a stress response program that activates TP53 (p53) and a
cascade of cellular events resulting in apoptosis, inhibition of the cell cycle or DNA
damage response (reviewed in e.g. [70]), commonly referred to as nucleolar stress
response [71] with activation of TP53 being a key hallmark [72]. A key mechanism
involves the release of RPs to the nucleoplasm, where several RPs bind and inhibit
MDM2, which again results in p53 stabilization and pathway activation [73, 74]. A recent
study showed that RP haploinsufficiency in the developing mouse limb bud also
activates a common TP53 cascade but results in TP53-dependent tissue-specific
changes of the translatome, which might confer the specificity often observed in
ribosomopathy [60]. The TP53-MDM2 feedback loop is the central molecular node in
response to a wide variety of stress signals, including in the human diseased adult heart
[75, 76]. As mentioned above, the transcriptomic response of the HLHS family 5H [18]
also showed activation of the TP53 pathway potentially due to an underlying
ribosomopathy. Since low RP levels induce a proliferation blockade that can be
overridden by p53-p21/CDKN1A KD, we hypothesize that RP levels may act as
signaling components sensing cellular fitness and with a functional outcome either
being p53 activation or non-activation. Such an RP–MDM2–p53 surveillance network
was previously proposed to be important in response to nutrient availability changes
and inhibition of oncogenic activity [77, 78]. Thus, the inhibition of the RP-MDM2-p53
axis might be a therapeutic avenue to consider for functional intervention, although
further studies are needed, to identify the upstream mechanisms leading to the *p53*
pathway activation observed in HLHS proband cells.

Heart-specific KD of the *RpS15Aa* in *Drosophila* causes constriction of larval
hearts and atrophy in adult hearts, due to heart loss during metamorphosis, which could
not be rescued by p53 reduction, unlike in hPSC-CMs and zebrafish. This might be due

to a different, context-dependent role of *p53* in flies previously reported to cause a
dwarfing, *Minute*-like phenotype [79]. We hypothesized that the loss of RPs in flies, in
conjunction with reduced protein synthesis, might cause nucleolar stress, triggering a
cell-intrinsic signaling cascade that prevents the heart to further differentiate and grow.

The role of the Hippo pathway to regulate cell growth/organ size, proliferation,
and survival, and its importance in cardiac biology is conserved between humans and
fly [80-83]. The Hippo-YAP pathway is a cell-intrinsic pathway that regulates
cardiomyocyte proliferation and thus heart size during development, as demonstrated
by the ability of activated Yap to induce postnatal CM regeneration [84]. Interestingly,
we find here that overexpression the *Drosophila* ortholog of YAP/TAZ, Yorkie, rescues
RpS15Aa KD-induced heart loss, dependent on its downstream factor *scalloped* (the
Drosophila ortholog of *TEAD1/2/3/4)* (Figure **5**). Of note, YAP1 is not only an important
regulator of cardiomyocyte proliferation in the embryo but also promotes cardiomyocyte
survival and growth in the postnatal heart [85, 86], which is in line with our findings.
Interestingly, a proband among the PCGC HLHS patients was transheterozygous for
mutations in *RPL15* and *TEAD4* [64], making this an interesting disease candidate pair.

Rapid Gene Discovery and Prioritization Approach for Complex Genetic Diseases.
Uncovering the genetic basis of polygenic and heterogeneous diseases, such as HLHS,
remains a significant challenge. This difficulty arises from the lack of experimental
approaches capable of rapidly determining the role and contribution of genetic variants,
as well as their epistatic relationships, in generating disease-associated phenotypes.
The current state-of-the-art approach involves using CRISPR-mediated editing or
correction of gene variants [87], which is effective for analyzing single-family pedigrees.
However, this method is impractical for prioritizing the large number of candidate genes
identified through cohort-wide analyses. Consequently, progress in gene discovery for
HLHS has been limited in recent years [12, 88]. In this study, we aimed to address
these limitations by employing a HT and unbiased exploration of genes regulating a
conserved HLHS-relevant phenotype [41, 89-91], such as reduced CM proliferation, in
hiPSCs. Notably, results integration from a whole-genome functional screen in hiPSC-

derived CMs (**Figure 1**, RPs are top hits from the screen), genomic data from a HLHS
parent-proband cohort (**Figure 2**, RPs represent the most enriched gene class
containing rare damaging variants), hiPSC-CM phenotyping from a high value HLHS
family (75H), and functional validation in two independent *in vivo* model systems
(**Figure 3**), identified RPs as a novel class of HLHS-associated genes. While our study
highlights the potential of this approach for gene prioritization, additional research is
needed to confirm the causal roles of the identified genetic variants. In this context,
future research could also incorporate unbiased morphological assessments of disease
phenotypes [92] to identify additional disease-associated traits and regulatory pathways.
In conclusion, we propose that the approach outlined in this study offers a novel
framework for rapidly prioritizing genes in the context of complex genetic diseases,
paving the way for deeper insights into their underlying mechanisms.
571
572
573

Acknowledgements

This work was supported by a grant from the Wanek Foundation at Mayo Clinic
in Rochester, M.N., to J.L.T., T.J.N., T.M.O., R.B. and A.R.C. We gratefully
acknowledge the patients and families who participated in this study. We thank Marco
Tamayo for excellent technical assistance. This work was supported by National
Institutes of Health (R01 HL054732 to R.B.; R01 HL153645, R01 HL148827, R01
HL149992, R01 AG071464 to A.R.C.); by California Institute for Regenerative Medicine
(DISC2-10110 to A.R.C.); by the American Heart Association (AHA Predoctoral
Fellowship 18PRE33960593 to K.B.).

584
585
586

587 **MATERIALS AND METHODS**

588 **Key resources table**

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Genetic reagent (*D. melanogaster*)	*Hand*$^{4.2}$-Gal4	NA	PMID: 16467358	NA
Genetic reagent (*D. melanogaster*)	R94C02::tdTomato	Y. N. Jan lab	FBtp0137272	NA
Genetic reagent (*D. melanogaster*)	UAS-RpS15Aa^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0010198	v19198
Genetic reagent (*D. melanogaster*)	Df(RpS15Aa)	Bloomington Drosophila Stock Center (BDSC)	FBab0047266	39614
Genetic reagent (*D. melanogaster*)	UAS-RpL26^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0036825	v40402 v100280
Genetic reagent (*D. melanogaster*)	UAS-RpL36A^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0031980	v108391
Genetic reagent (*D. melanogaster*)	UAS-RpS15^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0034138	v35415 v104439
Genetic reagent (*D. melanogaster*)	UAS-RpL39^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0023170	v23578 v108821
Genetic reagent (*D. melanogaster*)	UAS-RpL3^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0020910	v109820
Genetic reagent (*D. melanogaster*)	UAS-yorkie	D. Pan	NA	NA
Genetic reagent (*D. melanogaster*)	UAS-Myc^{RNAi}	Bloomington Drosophila Stock Center (BDSC)	FBgn0262656	25784
Genetic reagent (*D. melanogaster*)	UAS-sd^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0003345	v101497
Genetic reagent (*D. melanogaster*)	*Df(3L)DocA*	I. Reim	Fbab0037663	NA
Genetic reagent (*D. melanogaster*)	tin^{EC40}	Bloomington Drosophila Stock Center (BDSC)	Fbal0032861	78560
Genetic reagent (*D. melanogaster*)	tin^{346}	Bloomington Drosophila Stock	Fbal0035787	92964

		Center (BDSC)		
Genetic reagent (*D. melanogaster*)	pnr[VX6]	Bloomington Drosophila Stock Center (BDSC)	Fbal0032468	6334
Genetic reagent (*D. melanogaster*)	Df(pnr)	Bloomington Drosophila Stock Center (BDSC)	Fbab0038315	7982
strain, strain background (*Danio rerio*)	Oregon AB wild-type			A commonly used wildtype strain
strain, strain background (*Danio rerio*)	*Tg(myl7:EGFP)[twu277]*	Tsai Lab, National Taiwan University	PMID:12950077	A transgenic line of zebrafish labeled with heart-specific EGFP fluorescence.
Strain, strain background (*Danio rerio*)	*Tg(myl7:H2A-mCherry)[sd12]*	Yelon Lab, University of California, San Diego	PMID:24075907	A transgenic line of zebrafish specifically expressing mCherry in cardiomyocyte nuclei.
Antibody	mouse monoclonal anti-ACTN1	Sigma	A7811	1:800
Antibody	Mouse monoclonal anti-POU5F1 (OCT4)	Sigma	P0082	1:500
Antibody	donkey polyclonal anti-mouse Alexa Fluor 568	Invitrogen	A10037	1:500
Antibody	chicken polyclonal anti-GFP	Aves Labs	GFP-1020	1:300
Antibody	rabbit polyclonal anti-mCherry	Rockland	600-401-P16S	1:200
Antibody	donkey polyclonal anti-chicken AlexaFluor 488	Jackson ImmunoResearch	703-545-155	1:200
Antibody	donkey polyclonal anti-rabbit AlexaFluor 568	Invitrogen	A10042	1:200
other	DAPI (iPSC) 500mg/mL	Sigma	D9542	1:1000
Antibody	mouse anti-Mhc (*Drosophila*)	DSHB	3E8-3D3	1:50
Antibody	anti-mouse-Alexa Fluor 488	Jackson Labs	115-545-003	1:500
other	Alexa Fluor 647 phalloidin	Invitrogen	A22287	1:500
other	DAPI (Zebrafish) 500 mg/mL	Invitrogen	D1306	1:200
Sequence based	RPS15A siRNA	Entrez Gene ID: 6210	Dharmacon	On-Target plus,

reagent				individual sequence
sequence-based reagent	TP53 siRNA	Entrez Gene ID: 7157	Dharmacon	On-Target plus, Individual Sequence
sequence-based reagent	CDKN1A siRNA	Entrez Gene ID: 1026	Dharmacon	On-Target plus, SmartPool
sequence-based reagent	TP53	371502118c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CDKN1A	310832423c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CCNB1	356582356c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CCNB2	332205979c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CDK1	281427275c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	MCM2	33356546c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	RPS15A	71772358c2	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	GAPDH	Hs.PT.45.8326	IDT Integrated DNA technologies, Coralville, IA	Expression level
commercial assay or kit	EdU	Click-it Plus EdU Imaging Kit	Life Technologies	
software, algorithm	Prism v7 and v8		GraphPad Software	

Study subjects

Written informed consent was obtained for HLHS probands and family members under a research protocol approved by the Mayo Clinic Institutional Review Board. Cardiac anatomy was assessed by echocardiography. Candidate genes were identified and prioritized by WGS of genomic DNA and RNA sequencing of patient-specific iPSC and cardiomyocytes. Methods for genomic analyses, RNA Sequencing, iPSC technology, bioinformatics and statistics are described in the Online Appendix. Data are available at NCBI GEO database.

WGS and bioinformatic strategies

Our methods for family phenotyping, WGS, variant filtering, and candidate gene prioritization in the rare HLHS-CHD family and 25 HLHS proband-parent trios have been previously described [7, 9, 18]. In brief, WGS of DNA isolated from blood or cheek swabs was performed on a HiSeq 4000 platform at the Mayo Clinic Medical Genome Facility. BAM files underwent primary and secondary analyses using an established workflow with standard data quality metrics, and reads were aligned to the human hg38 reference genome. Variant call format files with single nucleotide variants and small insertion-deletion (indel) calls were analyzed using Ingenuity Variant Analysis software and knowledge database (Qiagen). To retain only high-confidence data, variants were required to have a base call quality of at least 20 and to pass Variant Quality Score Recalibration. Functionally annotated coding and regulatory variants underwent primary filtering and prioritization by an iterative approach with variants required to have a minor allele frequency (MAF) <0.01 across all races in gnomAD v2.1.[93] Variants predicted to impact protein structure were retained and included missense, frameshift, stop-gain, stop-loss, canonical splice and non-canonical variants predicted to disrupt splicing based upon MaxEntScan[94]. Regulatory variants were defined as those that (a) impact a microRNA or microRNA binding site (b) reside in an enhancer binding site annotated in the VISTA database (http://enhancer.lbl.gov/) or (c) disrupt a predicted promoter or transcription factor binding site informed by the position-weighted matrices available in JASPAR (http://jaspar.cgb.ki.se/). Genes harboring a rare functional variant were further required to have upper quartile cardiac expression during mouse embryonic (e14.5) (Homsy et al., 2015) or human fetal heart development (ranked percentiles from RNASeq experiments available in ENCODE: ENCSR047LLJ (120 day male); ENCSR863BUL (91 day female); ENCSR000AEZ (28 week female and 19 week female) (Davis et al., 2018).

For the HLHS-CHD family, a secondary segregation filter was applied to model autosomal dominant inheritance with incomplete penetrance, which required sharing of prioritized rare variants between affected family members. For the poor-outcome HLHS

proband-parent trios, a secondary Mendelian filter was applied to identify major-effect
driver variants that arose *de novo* or fit recessive modes of inheritance (i.e.,
homozygosity, hemizygosity, compound heterozygosity).

To determine whether certain gene networks were over-represented, two online
bioinformatics tools were used. First, STRING[39] was used to investigate experimental
and predicted protein-protein and genetic interactions, and clustering of RP genes was
demonstrated when the highest stringency filter was applied. In addition, PANTHER[38]
was employed to identify potential enrichment of genes by ontology classification.

Generation of hPSC-VCMs

Id1 overexpressing hPSCs [33, derived from, 95] were dissociated with 0.5 mM
EDTA (ThermoFisher Scientific) in PBS without $CaCl_2$ and $MgCl_2$ (Corning) for 7 min at
room temperature. hPSC were resuspended in mTeSR-1 media (StemCell
Technologies) supplemented with 2 µM Thiazovivin (StemCell Technologies) and plated
in a Matrigel-coated 12-well plate at a density of 3 x 10^5 cells per well. After 24 hours
after passage, cells were fed daily with mTeSR-1 media (without Thiazovivin) for 3-5
days until they reached ≥ 90% confluence to begin differentiation. hPSC-VCMs were
differentiated as previously described [95]. At day 0, cells were treated with 6 µM
CHIR99021 (Selleck Chemicals) in S12 media [96]. for 48 hours. At day 2, cells were
treated with 2 µM Wnt-C59 (Selleck Chemicals), an inhibitor of WNT pathway, in S12
media. 48 hours later (at day 4), S12 media is fully changed. At day 5, cells were
dissociated with TrypLE Express (Gibco) for 2 min and blocked with RPMI (Gibco)
supplemented with 10% FBS (Omega Scientific). Cells were resuspended in S12 media
supplemented with 4 mg/L Recombinant Human Insulin (Gibco) (S12+ media) and 2 µM
Thiazovivin and plated onto a Matrigel-coated 12-well plate at a density of 9 x 10^5 cells
per well. S12+ media was changed at day 8 and replaced at day 10 with RPMI (Gibco)
media supplemented with 213 µg/µL L-ascorbic acid (Sigma), 500 mg/L BSA-FV
(Gibco), 0.5 mM L-carnitine (Sigma) and 8 g/L AlbuMAX Lipid-Rich BSA (Gibco; CM
media). Typically, hPSC-ACMs start to beat around day 10. At day 15, cells were
purified with lactate media (RPMI without glucose, 213 µg/µL L-ascorbic acid, 500 mg/L

BSA-FV and 8 mM Sodium-DL-Lactate (Sigma), for 4 days. At day 19, media was
replaced with CM media.

siRNA transfection, proliferation assay and immunostaining in hPSC-VCMs

At day 25 of differentiation, hPSC-VCMs were dissociated with TrypLE Select
10X (Gibco), 10 min and neutralized with RPMI supplemented with 10% FBS. Cells
were resuspended in RPMI with 2% KOSR (Gibco) and 2% B27 50X with vitamin A (Life
Technologies) supplemented with 2 µM Thiazovivin and plated at a density of 5,000
cells/well in a Matrigel-coated 384-well plate. hPSC-VCMs were transfected with siRNA
(Dharmacon: ON-TARGETplus, custom RNAi cherry-pick libraries 0.1 nmol). For the
whole genome screening, siRNAs directed to 18,000 human genes were purchased
from the Genomic Center Facility at SBP at a final concentration of 25 nM using
lipofectamine RNAiMax (ThermoFisher) and opti-MEM (Gibco). 48 hours post-
transfection, cells were labelled with 10 µM EdU (ThermoFisher). After 24h of EdU
incubation, cells were fixed with 4% paraformaldehyde for 30 min and blocked in
blocking buffer (10% Horse Serum, 10% Gelatin and 0.5% Triton X-100) for 20 min.
EdU was detected according to protocol and cells were stained with cardiac specific
marker ACTN2 (A7811, Sigma, dilution 1/800), secondary antibody Alexa Fluor 568
(Invitrogen, 1/500) and DAPI (1/1000) in Blocking Buffer. Cells were imaged with
ImageXpress Micro XLS microscope (Molecular Devices) and custom algorithms were
used to quantify % of EdU+ ACTN1+ hPSC-VCMs and the number of ACTN1+ cells. To
quantify TP53 levels in hPSC-VCMs, cells were stained with Phospho-p53 (700439,
ThermoFisher, 1/500), counterstained with ACTN1 (anti-mouse A7811, Sigma, or anti-
rat ab50599, Abcam), and imaged and quantified with ImageXpress microscope. Whole
genome screening was performed in one-replicate. All the other siRNAs experiments
were performed in quadruplicates.

RNA-seq and data analysis

hPSCs and hPSC-derived CMs were transfected with 25nM final concentrations of
siRNA against RPS15A, RPL39 and with scrambled control siRNAs as above. 2 days
after siRNA transfection RPs KD were verified and confirmed by proliferation assay

(see above), and cells were pelleted and resuspended in 500µl TRIzol reagent followed
by total RNA extraction. Library preparation and sequencing of the samples was done at
La Jolla Institute of Immunology (La Jolla, CA). FASTQ files were processed using nf-
core/rnaseq (version 21.03.0.edge [97]). Differential gene expression was determined
using R/DESeq2 [98] and GO term enrichment was done using gprofiler2[99]. Analysis
scripts can be downloaded at github.com/gvogler. Raw reads and counts tables are
available at GEO accession number GSE207658.

Proliferation assay in parent/proband iPSCs

hPSCs were dissociated as described previously and plated in a Matrigel-coated
384-well plate at a density of 3,000 cells per well. Cells were transfected with siRNA at
a final concentration of 25nM using lipofectamine RNAiMax and opti-MEM. After 3 days,
cells were labelled with 10 µM EdU for 1 hour. Cells were fixed with 4%
paraformaldehyde for 30 min and blocked in blocking buffer for 20 min. EdU was
detected according to the protocol and stained with stem cell specific marker OCT4
(P0082, Sigma, 1/500), secondary antibody Alexa Fluor 568 and DAPI in Blocking
Buffer. Cells were imaged with ImageXpress microscope and % of EdU+ cells and
number of OCT4+ cells were quantified.

Quantitative Real Time PCR (RT-qPCR) in parent/proband iPSCs and hPSC-CMs

Total RNA was extracted using TRIzol and chloroform. 1ug of RNA was
converted in cDNA using QuantiTect Reverse Transcription kit (Qiagen). qRT-PCR was
performed using SYBR green (Biorad). Human primers sequences for qRT-PCR were
obtained from Harvard Primer Bank: TP53 (Primer Bank ID: 371502118c1), CDKN1A
(Primer Bank ID: 310832423c1), CCNB1 (Primer Bank ID: 356582356c1), CCNB2
(Primer Bank ID: 332205979c1), CDK1 (Primer Bank ID: 281427275c1), MCM2 (Primer
Bank ID: 33356546c1), RPS15A (Primer Bank ID: 71772358c2). All values were
normalized to *GAPDH (Primer Bank ID: 378404907c1)*. At least 3 independent
biological replicates were performed for each experiment.

Statistical analysis

717   To determine any statistical significance between experimental and control
718   groups in hPSC-VCMs and iPSCs from parent/proband trio, we calculated two-sided p
719   values with Student's t-test using GraphPad Prism 8.1.2 software.

Drosophila heart function studies

Drosophila orthologs were determined using the DIOPT database [100], and fly
stocks were obtained from the Vienna Drosophila Resource Center (VDRC) stock
center or Bloomington Drosophila Stock Center (BDSC) as indicated in the key source
table. For *in vivo* functional heart analysis, we developed a high-throughput method
based on genetically modified flies with cardiomyocyte-specific RFP fluorescence
(Klassen et al.). The reporter line by itself or combined with the heart-specific *Hand*[4.2]-
Gal4 driver (including all cardioblasts/cardiomyocytes, pericardial cells and wing hearts
throughout development starting at post-mitotic, mid-embryonic stages through
adulthood [101-103] was crossed to UAS-lines or mutant flies. For interaction studies a
fly line harboring the fluorescent reporter, *Hand*[4.2]-Gal4 driver and a Deficiency for
RpS15Aa was generated. Adult progeny flies were immobilized and exposed to
fluorescence light to record 5 sec high frame rate movies of the beating heart. Movies
were analyzed by fully automated quantification of contractility and rhythmicity
parameters of the heart [104]. Semi-intact adult fly hearts were filmed and analyzed
according to standard protocol [27, 105].

Immunostainings of the fly heart

The immunostaining of fly adult hearts was performed as described previously
[106]. In short, adult flies were dissected in a semi-intact fashion to expose the heart
according to protocol [27, 107]. Myofibrils were relaxed using 10mM EGTA followed by
fixation in 4% formaldehyde for 15 min. Hearts were washed with PBS + Triton (PBT;
0.03 % triton X-100) and stained using Alexa 647 phalloidin (Life Technologies) 2h at
room temperature (RT). For Mhc labelling, hearts were stained using anti-Mhc antibody
(1:50, incubation over night at 4°C) and after three washes with PBT, secondary

antibody was applied for 2 h at RT. Hearts were washed with PBT three times and PBS

one time and mounted using ProLong Gold mountant with DAPI (Life Technologies).

Heart preparations were imaged with the Imager.Z1 with an Apotome (Carl Zeiss),

Hamamatsu Orca Flash 4.0 and ZEN imaging software (Carl Zeiss).

Zebrafish Husbandry

All zebrafish experiments were performed in accordance with protocols approved

by IACUC. Zebrafish were maintained under standard laboratory conditions at 28.5°C.

In addition to Oregon AB wild-type, the following transgenic lines were used:

Tg(myl7:EGFP)^{twu277} [108] and *Tg(myl7:H2A-mCherry)^{sd12}* [109].

In zebrafish, gene expression was manipulated using standard microinjection of

morpholino (MO) antisense oligonucleotides [110]. In addition, we performed targeted

mutagenesis using CRISPR/Cas9 genome editing[111-113], to create insertion/deletion

(INDEL) mutations in relevant ribosomal genes (F0). Subsequently, zebrafish were

raised to 72 hours post fertilization (hpf), immobilized in low melt agarose and the hearts

were filmed and analyzed according to standard protocol[27].

MO sequence information:

All MOs were purchased from Gene Tools, LLC, synthesized at 300nmol, except

zebrafish p53 oligos at 100nmol.

Zebrafish *rpl13* 5'-UTR MO: TTGTTCACTCCGTCCTTAGCGGAAA

Zebrafish *rps15a* 5'-UTR MO: CGCACCATGATGCCAGTTCTGCAAT

Zebrafish *rpl39* 5'-UTR MO: GGATCGCAATCCGTTCACCACTATG

Zebrafish p53 MO: GCGCCATTGCTTTGCAAGAATTG

Zebrafish Control MO:

Zebrafish SOHA (Semi-automated Optical Heartbeat Analysis)

Larval zebrafish (72 hpf) were immobilized in a small amount of low melt agarose
(1.5%) and submerged in conditioned water. Beating hearts were imaged with direct
immersion optics and a digital high-speed camera (up to 200 frame/sec, Hamamatsu
Orca Flash) to record 30 seconds movies; images were captured using HC Image
(Hamamatsu Corp.). Cardiac function was analyzed from these high-speed movies
using semi-automatic optical heartbeat analysis software[27, 114], which for zebrafish
quantifies heart period (R-R interval), cardiac rhythmicity, as well as chamber size and
fractional area change. All hearts were imaged at room temperature (20-21°C).
Statistical analyses were performed using Prism software (Graphpad). Significance was
determined using two-tailed, unpaired student t-test or one-way ANOVA and Dunnett's
multiple comparisons post hoc test as appropriate.

Zebrafish Cardiomyocyte Cell Counts and Cardiac immunofluorescent imaging

To count cardiomyocytes, we used the expression of H2AmCherry in the nuclei
(*Tg(myl7:H2A-mCherry*)[109] to qualify as an individual cell, performed the "Spot"
function in Imaris to distinguish individual cells in reconstructions of confocal z-
stacks.[115, 116] To compare data sets, we used Prism software (GraphPad) to
perform Student's t-test with two-tail distribution. Graphs display mean and standard
deviation for each data set.

Whole-mount immunofluorescence was performed as previously described[18,
115-117] (see also key resources table). Confocal imaging was performed on an LSM
710 confocal microscope (Zeiss, Germany) with a 40x water objective. Exported z-
stacks were processed with Imaris software (Bitplane), Zeiss Zen, and Adobe Creative
Suite software (Photoshop and Illustrator 2020). All confocal images shown are
projection views of partial reconstructions from multiple z-stack slices, except where
noted that images are views of a single slice.

Zebrafish CRISPR/Cas9 experiments

Detailed steps were previously described[118] and we followed IDT manufacture
instruction for Complexes preparation. crRNA:tracrRNA Duplex Preparation: Target-
specific Alt-R® crRNA (sequence information see below) and common Alt-R®

804 tracrRNA were synthesized by IDT and each RNA was dissolved in duplex buffer (IDT)

805 as 100 μM stock solution. Stock solutions were stored at -20°C. To prepare the

806 crRNA:tracrRNA duplex, equal volumes of 100 μM Alt-R® crRNA and 100μM Alt-R®

807 tracrRNA stock solutions were mixed together and annealed by heating followed by

808 gradual cooling to room temperature by manufacture instruction: 95°C, 5 min on PCR

809 machine; cool to 25°C; cool to 4°C rapidly on ice. The 50 μM crRNA:tracrRNA duplex

810 stock solution was stored at -20°C. <u>Preparation of crRNA:tracrRNA:Cas9 RNP</u>

811 <u>Complexes:</u> Cas9 protein (Alt-R® S.p. Cas9 nuclease, v.3, IDT) was adjusted to 25 μM

812 stock solution in 20mM HEPES-NaOH (pH 7.5), 350 mM KCl, 20% glycerol, dispensed

813 as 8 ul aliquots, and stored at -80°C. 25μM crRNA:tracrRNA duplex was produced by

814 mixing equal volumes of 50 μM crRNA:tracrRNA duplex stock and duplex buffer (IDT).

815 We used 5 μM RNP complex. To generate 5μM crRNA:tracrRNA:Cas9 RNP complexes:

816 1 μl 25 μM crRNA:tracrRNA duplex was mixed with 1 μl 25 μM Cas9 stock, 2 μl H2O,

817 and 1 μl 0.25% phenol red solution. Prior to microinjection, the RNP complex solution

818 was incubated at 37°C, 5 min and then placed at room temperature. Approximately one

819 nanoliter of 5 μM RNP complex was injected into the cytoplasm of one-cell stage

820 embryos to generate F0 larva.

822 **IDT crRNA sequence information:**

823  All crRNAs were purchased from Integrated DNA Technologies, Inc., synthesized

824 at 2 nmol with standard desalting condition.

825 Dr.Cas9.RPS15A.1.AC: /AltR1/rUrU rGrUrU rGrUrC rArArU rCrUrC rArCrA rGrGrG

826 rGrUrU rUrUrA rGrArG rCrUrA rUrGrC rU/AltR2/

827 Dr.Cas9.RPS15A.1.AB: /AltR1/rGrC rGrUrA rCrUrA rUrGrA rCrUrU rUrArG rArGrC

828 rGrUrU rUrUrA rGrArG rCrUrA rUrGrC rU/AltR2/

829 Dr.Cas9.RPS17.1.AC:

830 /AltR1/rUrGrArCrUrUrCrCrArCrArUrUrArArCrArArGrCrGrUrUrUrUrArGrArGrCrUrArUrG

831 rCrU/AltR2/

Dr.Cas9.RPS28.1.AA:

/AlTR1/rCrUrGrGrGrArArGrArArCrUrGrGrCrUrCrCrCrArGrUrUrUrUrArGrArGrCrUrArUr

GrCrU/AlTR2/

Competing interests: None.

Table 1: Table 1 – Variants in ribosomal genes in HLHS probands. Abbreviations:
MAF – minor allele frequency; TFBS – transcription factor binding site; n.t. – not tested;
ASD – atrial septal defect; PLE - Protein-losing enteropathy; RV – right ventricle; RVEF
– right ventricular ejection fraction; RVEDP - right ventricular end diastolic pressure

Figure 1: Whole Genome siRNA Screen identified Ribosomal proteins as agonists
of cardiomyocyte proliferation. (A) High-throughput iPSC-derived CM proliferation
screen overview. **(B)** Screen result showing normalized % EdU+ CMs (X-axis) and
relative total number of CMs (Y-axis) upon knockdown of genome-wide siRNAs (18,055
siRNAs). siRNAs for RPL and RPS genes highlighted in red. **(C)** Representative
immunofluorescence images of proliferation (EdU incorporation, green, CM marker
ACTN2, red) of induced hPSC-CMs upon *TP53* and *RPS14* knockdown. Insets: nuclei
(DAPI) **(D)** Gene ontology enrichment analysis for WGS hits (BP, biological process;
FDR-corrected analysis using gprofiler2). (**E**) Overview of hits corresponding to top 4
non-redundant BP categories.

Figure 2: Ribosomal gene variants identified in HLHS. (A) Gene prioritization
scheme of 25 poor-outcome proband-parent trios. **(B)** Testing 292 HLHS candidate
genes from all poor-outcome families in CMs identified RPs as major regulators of
hPSC-CM proliferation (Normalized fraction of ACTN2+/EdU+ cells). **(C)** *Drosophila*
cardiac phenotypes induced by loss of RP genes affected in HLHS patients with poor
outcome. Heart is visualized by RFP expression specifically in cardiomyocytes
(R94C02::tdTom). Knockdown is achieved by sustained Gal4/UAS activity using
Hand4.2-Gal4. (**D**) Wild-type zebrafish larva, *rps17* and *rps28* CRISPR mutants and
rpl39 morphants at 72 hpf. *rpl39* morphants, injected with 1 ng MO in lateral view, show
mild edema. **(E)** Systolic surface area (SA) upon *rps17* and *rps28* CRISPR, and
diastolic SA after *rpl39* MO in the atrium and ventricle of zebrafish hearts.

Figure 3: Characterization of RPS15A from 75H HLHS index family. (A) (B) (C)
Prioritized candidate genes from the 75H family and relative hPSC-CM proliferation
capacity upon KD. (**D**) Representative immunofluorescence images of proliferation (EdU

incorporation, green; CM marker ACTN2, red) of induced hPSC-CMs upon siRPS15A
knockdown. **(E)** Heart-specific KD of *RpS15Aa* in *Drosophila* adult hearts cause loss of
heart tissue and is fully penetrant. **(F)** Representative immunofluorescence images of
control and *RpS15Aa*-RNAi shows partial heart loss (Myosin heavy chain, Mhc, red;
heart tissue-reporter, green). **(G)** CRISPR-mediated loss of *rps15a* in F_0 larval zebrafish
hearts causes decrease in CM number. **(H)** Representative immunofluorescence of
hearts and whole-mount images of control and *rps15a*-CRISPR F_0 larval hearts (CM
nuclei reporter, red).

879
880
Figure 4*: Loss of ribosomal gene function in CMs invokes TP53-stress response*.
(A) RNA sequencing of hPSC-CMs following siRNA-treatment for *RPL39* and *RPS15A*
shows both, convergent and divergent transcriptomic response. **(B)** GO term analysis of
differentially expressed genes following RP KD shows TP53-mediated response,
including upregulation of *CDKN1A*. **(C, D)** CDKN1A is highly upregulated in CMs
following *siRPS15A* treatment. **(E, F)** Reduced CM proliferation upon *RPS15A* KD is
mediated by *CDKN1A*/*TP53* and can be rescued upon their co-KD. **(G, H)** Larval
zebrafish CM number is reduced by morpholino-treatment for rps15a and can be
attenuated by P53 morpholino co-injection. Control and morphant (MO) hearts of 72 hpf
zebrafish larva stained with *Tg(myl7:EGFP)* and *Tg(myl7:H2A-mCherry)*. Note that
smaller heart with aberrant looping by *rps15a* MO is partially reversed by *p53* co-KD.
Student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001**.**

Figure 5: Rescue of *RpS15Aa* KD-mediated heart tube loss in Drosophila by
YAP/yorkie overexpression depending on its co-factor TEAD/scalloped. (A)
Representative images of RFP expressing fly hearts. RpS15Aa KD-mediated heart tube
loss can be partially rescued by overexpression of *yorkie* (*RpS15Aa* RNAi + *yorkie* OE) .
The rescue by *yki* OE depends on its co-factor *sd*. Flies were raised at 25 °C. **(B)**
Quantification of events presented as a percentage of flies exhibiting whole heart tube
versus partial heart loss (defined as 25-75% heart tube length compared to wildtype) or
no heart tube. Statistics: Fisher's exact test, *p<0.05. **(C)** Proposed signaling cascade

underlying cardiac growth, proliferation and differentiation impairment following
ribosomal stress (adapted from Baker et al., 2019).

Figure 6: *RPS15A* genetically interacts with cardiac transcription factors. (A) The
majority of cardiac transcription factors do not impact CM proliferation, except for e.g.,
HES4 and HOPX. **(B)** *TBX5* genetically interacts with *RPS15A* and *RPL39*. *siTBX5*
does not impact CM proliferation at 0.5, 1, 1.5 or 2nM si-concentration, and neither do
siRPS15A and *siRPL39* alone at 0.5nM. CM proliferation is reduced in siRP
backgrounds with increased titration of *siTBX5*. Two-way ANOVA for si*TBX5* dosage,
RP-knockdown and their interaction. **(C)** Representative fly heart segment (A4) from
control flies, heterozygous mutants ($tin^{346/+}$, $pnr^{VX6/+}$, $Doc^{Df/-}$, $Df(RpS15Aa)^{+/-}$) and
transheterozygous mutants. $tin^{+/-} = tin^{346}/+$, $pnr^{+/-} = Df(pnr)/+$, $Doc^{+/-} = Df(DocA)/+$. Note
the deformation and myofibrillar disorganization in the transheterozygous mutants. **(D)**
Quantification of adult *Drosophila* heart defects and genetic interaction. - Statistics:
Fisher's exact test on absolute numbers testing *normal* vs. *severely deformed* hearts.
*$p<0.05$, **$p<0.005$, ***$p<0.001$.

Figure 7: RP-dependent cardiac-specific regulation of cell proliferation. (A)
Schematic illustrating approach to identify novel RP-dependent and cardiac-specific
HLHS-associated gene network controlling CM proliferation. **(B)** Heatmap showing
differential expression (hiPSC-CMs vs hiPSCs) of genes regulating CM proliferation.
(C) Histogram showing effect of cardiac-specific and HLHS-associated genes on CM
proliferation. **(D)** Visualization of RP-dependent and cardiac-specific HLHS-associated
gene network (GeneMania). HLHS families. **(E)** Table of HLHS families harboring rare
and damaging variant in RP-dependent and cardiac-specific genes. **(F)** Histogram
showing lack of effect of siEWSR1 on OCT4+ hiPSCs. **(G)** Representative images of
OCT4+ cells in siControl and siEWSR1. **(H)** Histogram showing that siEWSR1
increases the % of CDKN1A+ CMs as compared to siControl. **(I)** Histogram showing
that siEWSR1 concomitantly decreases the % of EDU+ CMs as compared to siControl.
(J) Representative images showing immunostaining for CDKN1A (white), EDU (green)

and ACTN2 (Red) in siEWSR1 an siControl condition. **(K)** Pathway reconstruction of

cardiac and RP-dependent regulation of CM proliferation by HLHS-associated genes.

Chi-square test, *p<0.05, **p<0.005, ***p<0.001

Figure 8: Model for RP-dependent involvement in HLHS-associated phenotypes.

Schematic showing that combined prioritization and unbiased screening led to the

identification of a novel HLHS-associated gene network regulating CM proliferation as

potential disease-causing mechanism.

Supplemental Figure 1: (A, B) Confirmatory siRNA screening for all RP genes

confirms critical role for RPs in CM proliferation. (**C, D**) KD of RPs reduces proliferation

in human fibroblasts.

Supplemental Figure 2: Model organism phenotypes caused by loss of RP genes.

(A) Pedigree of the extended 75H family investigated for shared variants between

HLHS proband (black square) and distant cousin with CHD (half-filled circle). (**B**) **(C)**

Diastolic and **(D)** and Systolic Surface Area after rps15a CRISPR. Statistics: Mann-

Whitney test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001

Supplemental Figure 3: *rps15a* zebrafish larval morphants show heart

dysfunction and reduction in cardiomyocyte number. (A) Lateral view (head to the

right) of a wild-type control zebrafish larva (top) and a morphant (bottom) following

injection of 2 ng/µl *rps15a* morpholino (MO). The morphant exhibits near normal

body/tail but notable pericardial edema (arrowhead). **(B)** Control (left) and morphant

hearts (right) stained with Tg(*myl7*:*EGFP*) and Tg(*myl7*:*H2A-mCherry*). Note the smaller

heart with aberrant looping in morphant heart. **(C)** Total CM counts (mCherry+ cells) in

control and *rps15a* morphants shown in (B). **(D)** Fractional area change (FAC) in control

and *rps15a* morphants. **(E-H)** Injection of Control MO had little effect on zebrafish

cardiac function. There was no significant difference between uninjected and injected

controls with respect to (**E**) Systolic or (**F**) Diastolic Surface Areas, (**G**) Fractional Area

Change or (**H**) R-R intervals. Student's t-test, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.

Supplemental Figure 4: Proliferation and heart function is regulated by RPS15A
via TP53 in CMs and zebrafish. (A, B) The number of *siRPS15A*-treated CMs is
strongly reduced, which can be attenuated by co-KD of *CDKN1A* or *TP53*. **(C,D)** Loss
of *rps15a* causes strong reduction in zebrafish heart contractility (measured by
Fractional Area Change, **C**) and heart period **(D)**, which can be rescued by co-KD of
p53 in both, zebrafish heart atrium and ventricle.

Supplemental Figure 5: Genetic interaction between *RpS15Aa/RPS15A* and
***cabeza/EWSR1* (A, B)** Dose-dependent inhibition of hPSC-CMs proliferation by
RPS15A KD. **(C)** Diastolic Diameter (DD), and Heart Period (HP) of 3-week-old female
control and heterozygous RpS15Aa deficient flies with or without additional
heterozygous mutation in tinman, pannier or Dorsocross. Statistics: Kruskal-Wallis,
*p<0.05, **p<0.005, ***p<0.001, ****p<0.0001. Note, the prolonged HP in
transheterozygous mutants for Df(RpS15Aa) and tinman. **(D, E)** FAC, and HP of the
atria and ventricles at 72 hpf in zebrafish embryos injected with 0.5 ng rps15a and/or 1
ng nkx2.7 MOs (**E**) or 0.5 ng rps15a and/or 0.5 ng tbx5 MOs (F**).** Note, that FAC and
heart periods show synergistic genetic interaction between rps15a and nkx2.7 and
tbx5a. Statistics: 2-Way ANOVA, *p<0.05, **p<0.01, ****p<0.0001.**(F)** Systolic intervals
(SI) of 1-week-old adult flies upon heart-specific knockdown of *cabeza* (*caz^{32990}* or
caz^{34839} RNAi) using Hand$^{4.2}$-Gal4 driver with or without additional RpS15Aa
heterozygosity (RpS15Aa$^{Df/+}$) and age-matched controls. Automated analysis of SI
depicted as median with interquartile range obtained from 5s high-frame-rate videos.
Statistics: Kruskal-Wallis test, *p<0.05, **p<0.01, ***p<0.001.

Supplemental Table 1: Whole genome siRNA screen results table.

Supplemental Table 2: 292 filtered variants from poor-outcome HLHS probands.
MOI – mode of inheritance

Supplemental Table 3: Segregating variants of 75H proband.

Supplemental Table 4: Subset from all 292 genes that cause CM proliferation
defects and/or fly heart defects

Supplemental Tables 5-8: Differential gene expression lists for siRPL39 and
siRPS15A in hPSCs and CMs.

Supplemental Table 9: 12 genes prioritized after RNAseq and WGS analysis.

1000

1001

1002

1003

1004

REFERENCES

1.   Gordon BM, Rodriguez S, Lee M, Chang R-K. Decreasing number of deaths of infants with hypoplastic left heart syndrome. J Pediatr. 2008;153(3):354-8. doi: 10.1016/j.jpeds.2008.03.009.

2.   Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153(6):807-13. doi: 10.1016/j.jpeds.2008.05.059.

3.   Crucean A, Alqahtani A, Barron DJ, Brawn WJ, Richardson RV, O'Sullivan J, et al. Re-evaluation of hypoplastic left heart syndrome from a developmental and morphological perspective. Orphanet J Rare Dis. 2017;12(1):138. doi: 10.1186/s13023-017-0683-4.

4.   Konno Y, Toki T, Tandai S, Xu G, Wang R, Terui K, et al. Mutations in the ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia. Haematologica. 2010;95(8):1293-9. doi: 10.3324/haematol.2009.020826.

5.   Agopian AJ, Goldmuntz E, Hakonarson H, Sewda A, Taylor D, Mitchell LE, et al. Genome-Wide Association Studies and Meta-Analyses for Congenital Heart Defects. Circ Cardiovasc Genet. 2017;10(3):e001449. doi: 10.1161/CIRCGENETICS.116.001449.

6.   Martin LJ, Pilipenko V, Benson DW. Role of Segregation for Variant Discovery in Multiplex Families Ascertained by Probands With Left Sided Cardiovascular Malformations. Front Genet. 2018;9:729. doi: 10.3389/fgene.2018.00729.

7.   Theis JL, Hrstka SCL, Evans JM, O'Byrne MM, de Andrade M, O'Leary PW, et al. Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome. Hum Genet. 2015;134(9):1003-11. doi: 10.1007/s00439-015-1582-1.

8.   Elliott DA, Kirk EP, Yeoh T, Chandar S, McKenzie F, Taylor P, et al. Cardiac homeobox gene NKX2-5 mutations and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome. J Am Coll Cardiol. 2003;41(11):2072-6. doi: 10.1016/s0735-1097(03)00420-0.

9.   Theis JL, Zimmermann MT, Evans JM, Eckloff BW, Wieben ED, Qureshi MY, et al. Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction. Circ Cardiovasc Genet. 2015;8(4):564-71. doi: 10.1161/CIRCGENETICS.115.001070.

10.   Zanon A, Kalvakuri S, Rakovic A, Foco L, Guida M, Schwienbacher C, et al. SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila. Hum Mol Genet. 2017;26(13):2412-25. doi: 10.1093/hmg/ddx132. PubMed PMID: 28379402.

11.   Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL, Fletcher WH. Identification of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis (DGGE). Mutat Res. 2001;479(1-2):173-86. doi: 10.1016/s0027-5107(01)00160-9.

12.   Yagi H, Liu X, Gabriel GC, Wu Y, Peterson K, Murray SA, et al. The Genetic Landscape of Hypoplastic Left Heart Syndrome. Pediatr Cardiol. 2018;39(6):1069-81. doi: 10.1007/s00246-018-1861-4. PubMed PMID: 29569026.

13.   Yaich L, Ooi J, Park M, Borg JP, Landry C, Bodmer R, et al. Functional analysis of the Numb phosphotyrosine-binding domain using site-directed mutagenesis. The Journal of biological chemistry. 1998;273(17):10381-8. PubMed PMID: 9553095.

14.   Grossfeld P, Ye M, Harvey R. Hypoplastic left heart syndrome: new genetic insights. J Am Coll Cardiol. 2009;53(12):1072-4. doi: 10.1016/j.jacc.2008.12.024. PubMed PMID: 19298922.

15.   Miao Y, Tian L, Martin M, Paige SL, Galdos FX, Li J, et al. Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart Syndrome. Cell Stem Cell. 2020;27(4):574-89.e8. doi: 10.1016/j.stem.2020.07.015.

16.   Liu X, Yagi H, Saeed S, Bais AS, Gabriel GC, Chen Z, et al. The complex genetics of hypoplastic left heart syndrome. Nat Genet. 2017;49(7):1152-9. doi: 10.1038/ng.3870.

17.   Gaber N, Gagliardi M, Patel P, Kinnear C, Zhang C, Chitayat D, et al. Fetal reprogramming and senescence in hypoplastic left heart syndrome and in human pluripotent stem cells during cardiac differentiation. Am J Pathol. 2013;183(3):720-34. doi: 10.1016/j.ajpath.2013.05.022.

18.   Theis JL, Vogler G, Missinato MA, Li X, Nielsen T, Zeng X-XI, et al. Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome. eLife. 2020;9:e59554. doi: 10.7554/eLife.59554.

19.   Bodmer R. The gene tinman is required for specification of the heart and visceral muscles in Drosophila. Development. 1993;118(3):719-29.

20.   Bodmer R. Heart development in Drosophila and its relationship to vertebrates. Trends in Cardiovascular Medicine. 1995;5(1):21-8. doi: 10.1016/1050-1738(94)00032-Q.

21.   Cripps RM, Olson EN. Control of cardiac development by an evolutionarily conserved transcriptional network. Dev Biol. 2002;246(1):14-28. doi: 10.1006/dbio.2002.0666.

22.   Bodmer R, Frasch M. Chapter 1.2 - Development and Aging of the Drosophila Heart. In: Rosenthal N, Harvey RP, editors. Heart Development and Regeneration. Boston: Academic Press; 2010. p. 47-86.

23.   Bier E, Bodmer R. Drosophila, an emerging model for cardiac disease. Gene. 2004;342(1):1-11. doi: 10.1016/j.gene.2004.07.018.

24.   Evans SM, Yelon D, Conlon FL, Kirby ML. Myocardial lineage development. Circ Res. 2010;107(12):1428-44. doi: 10.1161/CIRCRESAHA.110.227405.

25.   Bakkers J. Zebrafish as a model to study cardiac development and human cardiac disease. Cardiovasc Res. 2011;91(2):279-88. doi: 10.1093/cvr/cvr098.

26.   Liu J, Stainier DYR. Zebrafish in the study of early cardiac development. Circ Res. 2012;110(6):870-4. doi: 10.1161/CIRCRESAHA.111.246504.

27.   Fink M, Callol-Massot C, Chu A, Ruiz-Lozano P, Izpisua Belmonte JC, Giles W, et al. A new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish, and embryonic mouse hearts. Biotechniques. 2009;46(2):101-13. doi: 10.2144/000113078.

28.   Huang G-Y, Xie L-J, Linask KL, Zhang C, Zhao X-Q, Yang Y, et al. Evaluating the role of connexin43 in congenital heart disease: Screening for mutations in patients with outflow tract anomalies and the analysis of knock-in mouse models. J Cardiovasc Dis Res. 2011;2(4):206-12. doi: 10.4103/0975-3583.89804.

29.   Yu MS, Spiering S, Colas AR. Generation of First Heart Field-like Cardiac Progenitors and Ventricular-like Cardiomyocytes from Human Pluripotent Stem Cells. JoVE (Journal of Visualized Experiments). 2018;(136):e57688. doi: 10.3791/57688.

30.   Paige SL, Galdos FX, Lee S, Chin ET, Ranjbarvaziri S, Feyen DAM, et al. Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome. Circulation. 2020;142(16):1605-8. doi: 10.1161/CIRCULATIONAHA.119.045317.

31.   Diez-Cunado M, Wei K, Bushway PJ, Maurya MR, Perera R, Subramaniam S, et al.
miRNAs that Induce Human Cardiomyocyte Proliferation Converge on the Hippo Pathway. Cell
reports. 2018;23(7):2168-74. Epub 2018/05/17. doi: 10.1016/j.celrep.2018.04.049. PubMed
PMID: 29768213; PubMed Central PMCID: PMCPMC6261450.
32.   Murphy SA, Miyamoto M, Kervadec A, Kannan S, Tampakakis E, Kambhampati S, et al.
PGC1/PPAR drive cardiomyocyte maturation at single cell level via YAP1 and SF3B2. Nature
communications. 2021;12(1):1648. Epub 2021/03/14. doi: 10.1038/s41467-021-21957-z.
PubMed PMID: 33712605; PubMed Central PMCID: PMCPMC7955035.
33.   Cunningham TJ, Yu MS, McKeithan WL, Spiering S, Carrette F, Huang C-T, et al. Id
genes are essential for early heart formation. Genes Dev. 2017;31(13):1325-38. doi:
10.1101/gad.300400.117.
34.   Cunningham TJ, Yu MS, McKeithan WL, Spiering S, Carrette F, Huang CT, et al. Id
genes are essential for early heart formation. Genes & development. 2017. doi:
10.1101/gad.300400.117. PubMed PMID: 28794185.
35.   Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2
oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and
chemotherapy. Proc Natl Acad Sci U S A. 2003;100(20):11636-41. Epub 2003/09/18. doi:
10.1073/pnas.1934692100.   PubMed   PMID: 13130078;   PubMed   Central   PMCID:
PMCPMC208810.
36.   Yuan LL, Green A, David L, Dozier C, Recher C, Didier C, et al. Targeting CHK1
inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia. Leuk Res.
2014;38(11):1342-9. Epub 2014/10/05. doi: 10.1016/j.leukres.2014.08.020. PubMed PMID:
25281057.
37.   Zhou X, Liao WJ, Liao JM, Liao P, Lu H. Ribosomal proteins: functions beyond the
ribosome. J Mol Cell Biol. 2015;7(2):92-104. Epub 2015/03/05. doi: 10.1093/jmcb/mjv014.
PubMed PMID: 25735597; PubMed Central PMCID: PMCPMC4481666.
38.   Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more
genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic
Acids Res. 2019;47(D1):D419-D26. doi: 10.1093/nar/gky1038.
39.   Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING
v11: protein-protein association networks with increased coverage, supporting functional
discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D13.
doi: 10.1093/nar/gky1131.
40.   Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and
generating dominant phenotypes. Development. 1993;118(2):401-15.
41.   Gaber N, Gagliardi M, Patel P, Kinnear C, Zhang C, Chitayat D, et al. Fetal
reprogramming and senescence in hypoplastic left heart syndrome and in human pluripotent stem
cells   during   cardiac   differentiation.   Am   J   Pathol.   2013;183(3):720-34.   doi:
10.1016/j.ajpath.2013.05.022. PubMed PMID: 23871585.
42.   Liu X, Yagi H, Saeed S, Bais AS, Gabriel GC, Chen Z, et al. The complex genetics of
hypoplastic left heart syndrome. Nature genetics. 2017;49(7):1152-9. doi: 10.1038/ng.3870.
PubMed PMID: 28530678.
43.   Schroeder AM, Allahyari M, Vogler G, Missinato MA, Nielsen T, Yu MS, et al. Model
system identification of novel congenital heart disease gene candidates: focus on RPL13. Hum
Mol Genet. 2019;28(23):3954-69. doi: 10.1093/hmg/ddz213.

44. Fink M, Callol-Massot C, Chu A, Ruiz-Lozano P, Izpisua Belmonte JC, Giles W, et al. A
new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish,
and embryonic mouse hearts. Biotechniques. 2009;46(2):101-13. doi: 10.2144/000113078.
PubMed PMID: 19317655; PubMed Central PMCID: PMC2855226.
45. Uechi T, Nakajima Y, Nakao A, Torihara H, Chakraborty A, Inoue K, et al. Ribosomal
Protein Gene Knockdown Causes Developmental Defects in Zebrafish. PLOS ONE.
2006;1(1):e37. doi: 10.1371/journal.pone.0000037.
46. Ikeda F, Yoshida K, Toki T, Uechi T, Ishida S, Nakajima Y, et al. Exome sequencing
identified RPS15A as a novel causative gene for Diamond-Blackfan anemia. Haematologica.
2017;102(3):e93-e6. doi: 10.3324/haematol.2016.153932.
47. Miura GI, Yelon D. A Guide to Analysis of Cardiac Phenotypes in the Zebrafish Embryo.
Methods Cell Biol. 2011;101:161-80. doi: 10.1016/B978-0-12-387036-0.00007-4.
48. Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28):3943-56.
Epub 2017/03/14. doi: 10.1038/onc.2016.502. PubMed PMID: 28288132; PubMed Central
PMCID: PMCPMC5511239.
49. Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA, et al. p53
activation by knockdown technologies. PLoS Genet. 2007;3(5):e78. doi:
10.1371/journal.pgen.0030078.
50. Furth N, Aylon Y, Oren M. p53 shades of Hippo. Cell Death Differ. 2018;25(1):81-92.
doi: 10.1038/cdd.2017.163.
51. Baker NE, Kiparaki M, Khan C. A potential link between p53, cell competition and
ribosomopathy in mammals and in Drosophila. Dev Biol. 2019;446(1):17-9. doi:
10.1016/j.ydbio.2018.11.018.
52. Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, et al. Drosophila
p53 is a structural and functional homolog of the tumor suppressor p53. Cell. 2000;101(1):91-
101. doi: 10.1016/S0092-8674(00)80626-1. PubMed PMID: 10778859.
53. Raj N, Bam R. Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53 Family
Proteins: Mechanisms and Outcomes in Cancer. Front Cell Dev Biol. 2019;7:159. Epub
20190809. doi: 10.3389/fcell.2019.00159. PubMed PMID: 31448276; PubMed Central PMCID:
PMCPMC6695833.
54. Monroe TO, Hill MC, Morikawa Y, Leach JP, Heallen T, Cao S, et al. YAP Partially
Reprograms Chromatin Accessibility to Directly Induce Adult Cardiogenesis In Vivo.
Developmental Cell. 2019;48(6):765-79.e7. doi: 10.1016/j.devcel.2019.01.017.
55. Kang J, Brajanovski N, Chan KT, Xuan J, Pearson RB, Sanij E. Ribosomal proteins and
human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther.
2021;6(1):323. Epub 2021/09/01. doi: 10.1038/s41392-021-00728-8. PubMed PMID: 34462428;
PubMed Central PMCID: PMCPMC8405630.
56. Bruneau BG, Logan M, Davis N, Levi T, Tabin CJ, Seidman JG, et al. Chamber-specific
cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. Developmental biology.
1999;211(1):100-8. doi: 10.1006/dbio.1999.9298. PubMed PMID: 10373308.
57. Qian L, Wythe JD, Liu J, Cartry J, Vogler G, Mohapatra B, et al. Tinman/Nkx2-5 acts via
miR-1 and upstream of Cdc42 to regulate heart function across species. J Cell Biol.
2011;193(7):1181-96. doi: 10.1083/jcb.201006114. PubMed PMID: 21690310; PubMed Central
PMCID: PMCPMC3216339.

58.   Lee KH, Xu Q, Breitbart RE. A new tinman-related gene, nkx2.7, anticipates the
expression of nkx2.5 and nkx2.3 in zebrafish heart and pharyngeal endoderm. Dev Biol.
1996;180(2):722-31. doi: 10.1006/dbio.1996.0341.
59.   Targoff KL, Schell T, Yelon D. Nkx Genes Regulate Heart Tube Extension and Exert
Differential Effects on Ventricular and Atrial Cell Number. Dev Biol. 2008;322(2):314-21. doi:
10.1016/j.ydbio.2008.07.037.
60.   Tiu GC, Kerr CH, Forester CM, Krishnarao PS, Rosenblatt HD, Raj N, et al. A p53-
dependent translational program directs tissue-selective phenotypes in a model of
ribosomopathies. Developmental Cell. 2021;0(0). doi: 10.1016/j.devcel.2021.06.013.
61.   McGowan KA, Pang WW, Bhardwaj R, Perez MG, Pluvinage JV, Glader BE, et al.
Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic
syndrome. Blood. 2011;118(13):3622-33. Epub 20110725. doi: 10.1182/blood-2010-11-318584.
PubMed PMID: 21788341; PubMed Central PMCID: PMCPMC3186336.
62.   Flucke U, van Noesel MM, Siozopoulou V, Creytens D, Tops BBJ, van Gorp JM, et al.
EWSR1-The Most Common Rearranged Gene in Soft Tissue Lesions, Which Also Occurs in
Different Bone Lesions: An Updated Review. Diagnostics (Basel). 2021;11(6). Epub 20210615.
doi: 10.3390/diagnostics11061093. PubMed PMID: 34203801; PubMed Central PMCID:
PMCPMC8232650.
63.   Vlachos A, Osorio DS, Atsidaftos E, Kang J, Lababidi ML, Seiden HS, et al. The
Increased Prevalence of Congenital Heart Disease (CHD) in Children with Diamond Blackfan
Anemia (DBA) Suggests Unrecognized DBA as a Cause of CHD in the General Population: A
Report of the Diamond Blackfan Anemia Registry. Circ Genom Precis Med.
2018;11(5):e002044. doi: 10.1161/CIRCGENETICS.117.002044.
64.   Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, et al. Contribution of rare
inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet.
2017;49(11):1593-601. doi: 10.1038/ng.3970.
65.   Ye M, Coldren C, Liang X, Mattina T, Goldmuntz E, Benson DW, et al. Deletion of
ETS-1, a gene in the Jacobsen syndrome critical region, causes ventricular septal defects and
abnormal ventricular morphology in mice. Hum Mol Genet. 2010;19(4):648-56. Epub 20091126.
doi: 10.1093/hmg/ddp532. PubMed PMID: 19942620; PubMed Central PMCID:
PMCPMC2807373.
66.   Kathiriya IS, Rao KS, Iacono G, Devine WP, Blair AP, Hota SK, et al. Modeling Human
TBX5 Haploinsufficiency Predicts Regulatory Networks for Congenital Heart Disease.
Developmental   cell.   2021;56(3):292-309   e9.   Epub   2020/12/16.   doi:
10.1016/j.devcel.2020.11.020. PubMed PMID: 33321106; PubMed Central PMCID:
PMCPMC7878434.
67.   Ang YS, Rivas RN, Ribeiro AJS, Srivas R, Rivera J, Stone NR, et al. Disease Model of
GATA4 Mutation Reveals Transcription Factor Cooperativity in Human Cardiogenesis. Cell.
2016;167(7):1734-49 e22. doi: 10.1016/j.cell.2016.11.033. PubMed PMID: 27984724; PubMed
Central PMCID: PMCPMC5180611.
68.   Tanaka M, Yamaguchi S, Yamazaki Y, Kinoshita H, Kuwahara K, Nakao K, et al.
Somatic chromosomal translocation between Ewsr1 and Fli1 loci leads to dilated
cardiomyopathy in a mouse model. Sci Rep. 2015;5:7826. Epub 20150116. doi:
10.1038/srep07826. PubMed PMID: 25591392; PubMed Central PMCID: PMCPMC5379005.
69.   Ragni CV, Diguet N, Le Garrec JF, Novotova M, Resende TP, Pop S, et al. Amotl1
mediates sequestration of the Hippo effector Yap1 downstream of Fat4 to restrict heart growth.

Nat Commun. 2017;8:14582. Epub 20170227. doi: 10.1038/ncomms14582. PubMed PMID: 28239148; PubMed Central PMCID: PMCPMC5333361.

70.   Danilova N, Gazda HT. Ribosomopathies: how a common root can cause a tree of pathologies. Dis Model Mech. 2015;8(9):1013-26. doi: 10.1242/dmm.020529.

71.   Boulon S, Westman BJ, Hutten S, Boisvert F-M, Lamond AI. The nucleolus under stress. Mol Cell. 2010;40(2):216-27. doi: 10.1016/j.molcel.2010.09.024.

72.   Yang K, Yang J, Yi J. Nucleolar Stress: hallmarks, sensing mechanism and diseases. Cell Stress. 2018;2(6):125-40. doi: 10.15698/cst2018.06.139.

73.   Dai M-S, Zeng SX, Jin Y, Sun X-X, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol. 2004;24(17):7654-68. doi: 10.1128/MCB.24.17.7654-7668.2004.

74.   Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16(5):369-77. doi: 10.1016/j.ccr.2009.09.024.

75.   Men H, Cai H, Cheng Q, Zhou W, Wang X, Huang S, et al. The regulatory roles of p53 in cardiovascular health and disease. Cell Mol Life Sci. 2021;78(5):2001-18. Epub 20201111. doi: 10.1007/s00018-020-03694-6. PubMed PMID: 33179140.

76.   Mak TW, Hauck L, Grothe D, Billia F. p53 regulates the cardiac transcriptome. Proc Natl Acad Sci U S A. 2017;114(9):2331-6. Epub 20170213. doi: 10.1073/pnas.1621436114. PubMed PMID: 28193895; PubMed Central PMCID: PMCPMC5338492.

77.   Deisenroth C, Zhang Y. The Ribosomal Protein-Mdm2-p53 Pathway and Energy Metabolism. Genes Cancer. 2011;2(4):392-403. doi: 10.1177/1947601911409737.

78.   Liu Y, Deisenroth C, Zhang Y. RP–MDM2–p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance. Trends Cancer. 2016;2(4):191-204. doi: 10.1016/j.trecan.2016.03.002.

79.   Cui Z, DiMario PJ. RNAi knockdown of Nopp140 induces Minute-like phenotypes in Drosophila. Mol Biol Cell. 2007;18(6):2179-91. doi: 10.1091/mbc.e07-01-0074.

80.   Barron DA, Kagey JD. The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med. 2014;3:25. doi: 10.1186/2001-1326-3-25.

81.   Del Re DP. The hippo signaling pathway: implications for heart regeneration and disease. Clin Transl Med. 2014;3(1):27. doi: 10.1186/s40169-014-0027-0.

82.   Yu L, Daniels JP, Wu H, Wolf MJ. Cardiac hypertrophy induced by active Raf depends on Yorkie-mediated transcription. Sci Signal. 2015;8(362):ra13-ra. doi: 10.1126/scisignal.2005719.

83.   Wang J, Liu S, Heallen T, Martin JF. The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration. Nat Rev Cardiol. 2018;15(11):672-84. doi: 10.1038/s41569-018-0063-3.

84.   Xiao Y, Leach J, Wang J, Martin JF. Hippo/Yap Signaling in Cardiac Development and Regeneration. Curr Treat Options Cardiovasc Med. 2016;18(6):38. doi: 10.1007/s11936-016-0461-y.

85.   von Gise A, Lin Z, Schlegelmilch K, Honor LB, Pan GM, Buck JN, et al. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(7):2394-9. doi: 10.1073/pnas.1116136109.

86.   Del Re DP, Yang Y, Nakano N, Cho J, Zhai P, Yamamoto T, et al. Yes-associated protein isoform 1 (Yap1) promotes cardiomyocyte survival and growth to protect against myocardial ischemic injury. J Biol Chem. 2013;288(6):3977-88. doi: 10.1074/jbc.M112.436311.

87.   Gifford CA, Ranade SS, Samarakoon R, Salunga HT, de Soysa TY, Huang Y, et al. Oligogenic inheritance of a human heart disease involving a genetic modifier. Science. 2019;364(6443):865-70. Epub 20190530. doi: 10.1126/science.aat5056. PubMed PMID: 31147515; PubMed Central PMCID: PMCPMC6557373.

88.   Birla AK, Brimmer S, Short WD, Olutoye OO, 2nd, Shar JA, Lalwani S, et al. Current state of the art in hypoplastic left heart syndrome. Front Cardiovasc Med. 2022;9:878266. Epub 20221028. doi: 10.3389/fcvm.2022.878266. PubMed PMID: 36386362; PubMed Central PMCID: PMCPMC9651920.

89.   Theis JL, Vogler G, Missinato MA, Li X, Nielsen T, Zeng XI, et al. Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome. eLife. 2020;9. Epub 2020/10/03. doi: 10.7554/eLife.59554. PubMed PMID: 33006316; PubMed Central PMCID: PMCPMC7581429.

90.   Miao Y, Tian L, Martin M, Paige SL, Galdos FX, Li J, et al. Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart Syndrome. Cell stem cell. 2020;27(4):574-89 e8. Epub 20200817. doi: 10.1016/j.stem.2020.07.015. PubMed PMID: 32810435; PubMed Central PMCID: PMCPMC7541479.

91.   Xu X, Jin K, Bais AS, Zhu W, Yagi H, Feinstein TN, et al. Uncompensated mitochondrial oxidative stress underlies heart failure in an iPSC-derived model of congenital heart disease. Cell stem cell. 2022;29(5):840-55 e7. Epub 20220407. doi: 10.1016/j.stem.2022.03.003. PubMed PMID: 35395180; PubMed Central PMCID: PMCPMC9302582.

92.   Bray MA, Singh S, Han H, Davis CT, Borgeson B, Hartland C, et al. Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nature protocols. 2016;11(9):1757-74. Epub 20160825. doi: 10.1038/nprot.2016.105. PubMed PMID: 27560178; PubMed Central PMCID: PMCPMC5223290.

93.   Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-43. doi: 10.1038/s41586-020-2308-7.

94.   Grodecká L, Kramárek M, Lockerová P, Kováčová T, Ravčuková B, Richterová R, et al. No major effect of the CDH1 c.2440-6C>G mutation on splicing detected in last exon-specific splicing minigene assay. Genes, Chromosomes and Cancer. 2014;53(9):798-801. doi: https://doi.org/10.1002/gcc.22186.

95.   Burridge PW, Holmström A, Wu JC. Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. Curr Protoc Hum Genet. 2015;87:21.3.1-.3.15. doi: 10.1002/0471142905.hg2103s87.

96.   Pei F, Jiang J, Bai S, Cao H, Tian L, Zhao Y, et al. Chemical-defined and albumin-free generation of human atrial and ventricular myocytes from human pluripotent stem cells. Stem Cell Research. 2017;19:94-103. doi: 10.1016/j.scr.2017.01.006.

97.   Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276-8. doi: 10.1038/s41587-020-0439-x. PubMed PMID: 32055031.

98.   Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8. PubMed PMID: 25516281; PubMed Central PMCID: PMCPMC4302049.

99.   Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic

Acids Res. 2019;47(W1):W191-W8. doi: 10.1093/nar/gkz369. PubMed PMID: 31066453; PubMed Central PMCID: PMCPMC6602461.

100.   Hu Y, Flockhart I, Vinayagam A, Bergwitz C, Berger B, Perrimon N, et al. An integrative approach to ortholog prediction for disease-focused and other functional studies. BMC Bioinformatics. 2011;12:357. doi: 10.1186/1471-2105-12-357. PubMed PMID: 21880147; PubMed Central PMCID: PMCPMC3179972.

101.   Han Z, Yi P, Li X, Olson EN. Hand, an evolutionarily conserved bHLH transcription factor required for Drosophila cardiogenesis and hematopoiesis. Development. 2006;133(6):1175-82. doi: 10.1242/dev.02285.

102.   Tögel M, Meyer H, Lehmacher C, Heinisch JJ, Pass G, Paululat A. The bHLH transcription factor hand is required for proper wing heart formation in Drosophila. Dev Biol. 2013;381(2):446-59. doi: 10.1016/j.ydbio.2013.05.027.

103.   Hallier B, Hoffmann J, Roeder T, Tögel M, Meyer H, Paululat A. The bHLH Transcription Factor Hand Regulates the Expression of Genes Critical to Heart and Muscle Function in Drosophila melanogaster. PLOS ONE. 2015;10(8):e0134204. doi: 10.1371/journal.pone.0134204.

104.   Vogler G. gvogler/FlyHearts-tdtK-Rscripts: First release of the R tdtK script. First ed: Zenodo; 2021.

105.   Cammarato A, Ocorr S, Ocorr K. Enhanced assessment of contractile dynamics in Drosophila hearts. BioTechniques. 2015;58(2):77-80. doi: 10.2144/000114255. PubMed PMID: 25652030.

106.   Alayari NN, Vogler G, Taghli-Lamallem O, Ocorr K, Bodmer R, Cammarato A. Fluorescent labeling of Drosophila heart structures. J Vis Exp. 2009;(32). doi: 10.3791/1423.

107.   Ocorr K, Vogler G, Bodmer R. Methods to assess Drosophila heart development, function and aging. Methods. 2014;68(1):265-72. doi: 10.1016/j.ymeth.2014.03.031.

108.   Huang C-J, Tu C-T, Hsiao C-D, Hsieh F-J, Tsai H-J. Germ-line transmission of a myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac myosin light chain 2 promoter of zebrafish. Dev Dyn. 2003;228(1):30-40. doi: 10.1002/dvdy.10356.

109.   Schumacher JA, Bloomekatz J, Garavito-Aguilar ZV, Yelon D. tal1 Regulates the formation of intercellular junctions and the maintenance of identity in the endocardium. Dev Biol. 2013;383(2):214-26. doi: 10.1016/j.ydbio.2013.09.019.

110.   Westerfield M. The zebrafish book: A guide for the laboratory use of zebrafish (Brachydanio rerio). 1993 ed: M. W, editor: University of Oregon Press; 1993.

111.   Talbot JC, Amacher SL. A streamlined CRISPR pipeline to reliably generate zebrafish frameshifting alleles. Zebrafish. 2014;11(6):583-5. doi: 10.1089/zeb.2014.1047.

112.   Gagnon JA, Valen E, Thyme SB, Huang P, Akhmetova L, Ahkmetova L, et al. Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs. PLOS ONE. 2014;9(5):e98186. doi: 10.1371/journal.pone.0098186.

113.   Irion U, Krauss J, Nüsslein-Volhard C. Precise and efficient genome editing in zebrafish using the CRISPR/Cas9 system. Development. 2014;141(24):4827-30. doi: 10.1242/dev.115584.

114.   Ocorr K, Fink M, Cammarato A, Bernstein SI, Bodmer R. Semi-automated Optical Heartbeat Analysis of Small Hearts. Journal of Visualized Experiments : JoVE. 2009;(31). doi: 10.3791/1435.

115.   Zeng X-XI, Yelon D. Cadm4 restricts the production of cardiac outflow tract progenitor cells. Cell Reports. 2014;7(4):951-60. doi: 10.1016/j.celrep.2014.04.013.

116.   Pradhan A, Zeng X-XI, Sidhwani P, Marques SR, George V, Targoff KL, et al. FGF
signaling enforces cardiac chamber identity in the developing ventricle. Development.
2017;144(7):1328-38. doi: 10.1242/dev.143719.
117.   Alexander J, Stainier DY, Yelon D. Screening mosaic F1 females for mutations affecting
zebrafish heart induction and patterning. Dev Genet. 1998;22(3):288-99. doi:
10.1002/(SICI)1520-6408(1998)22:3<288::AID-DVG10>3.0.CO;2-2.
118.   Hoshijima K, Jurynec MJ, Klatt Shaw D, Jacobi AM, Behlke MA, Grunwald DJ. Highly
Efficient CRISPR-Cas9-Based Methods for Generating Deletion Mutations and F0 Embryos that
Lack Gene Function in Zebrafish. Developmental Cell. 2019;51(5):645-57.e4. doi:
10.1016/j.devcel.2019.10.004.
1377

Figure 1

A

Day 25 hPSC-CMs

18,055 siRNAs tested

↓ 48h

EdU addition

→ 24h → Day 28

Automated Image Analysis

EdU assay ACTN2 DAPI

High-throughput Fluorescence Microscopy

B

- RPL/RPS genes
- all siRNAs

Relative hPSC-CM numbers (CM) — y-axis (0.0–1.5)

Relative EdU+, ACTN2+ CMs (EdU) — x-axis (0.0–2.0)

153 hits

Labels: CDKN1A, TP53, MDM2, CHEK1, RPS14

C

siControl, siCDKN1A, siTP53, siRPS14

ACTN2, EdU, DAPI

D

Enrichment of 153 top hits (Biological Process, BP)

Term	P value	Genes
nuclear-transcribed mRNA catabolic process	1.94e-43	41
protein targeting to ER	3.17e-56	41
establishment of protein localization to organelle	9.35e-30	43
Ribosome	1.78e-46	42
signal transduction by p53 class mediator	4.87e-02	8
positive regulation of vascular endothelial growth factor signaling pathway	3.20e-02	2
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	3.73e-02	3
regulation of signal transduction by p53 class mediator	6.05e-03	8
ribosomal small subunit assembly	2.09e-07	6
ribosomal large subunit assembly	2.03e-06	6
negative regulation of smoothened signaling pathway	4.71e-02	3

E

Genes — GO (BP)

Genes (listed): GLI3, SMOC2, CHEK1, TAF11, NOP53, RUNX2, MDM2, RMI2, FAU, RPL7, RPL6, VCP, RPL27, RPS10, RPS9, RPS14, RPS10A, RPL35A, RPL18, RPS16, RPS12, RPL8, RPL17, RPS6, RPLP0, RPS3A, RPL12, RPL38, RPS7, RPL9, RPS19, RPS27A, RPL24, RPL37A, RPS3, RPS11, RPS29, RPL19, RPL3, RPS5, RPS18, MRPL22, RPS4X, RPS13, CCBE1, RPS21, RPL23, RPL14, RPL21, RPL7A

% EdU+ CM scale: 0 – 0.5

RIBOSOME

NEGATIVE REGULATION OF SMOOTHENED SIGNALING

POSITIVE REGULATION OF VEGF SIGNALING

SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR

Figure 2

A

HLHS trios with poor outcome (n = 25)

Variant Filter
MAF<1%, Missense, Loss of Function, Canonical Splice, Promotor

Gene Filter
Upper Quartile Fetal Heart Expression

Inheritance Filter
De novo (26)
Compound heterozygous (196)
X-linked recessive (83)
Homozygous recessive (12)

Enrichment analysis
(292 unique genes)
Protein class
Ribosomal protein (5.24-fold, p=0.0028)
Cellular component
Large Ribosomal Subunit (7.27-fold, p=0.011)

B

Volcano plot: x-axis "Normalized EdU+ CMs" (0.0 to 1.5), y-axis "-log(P-Value)" (0 to ~90). Labeled points: RPS28, RPS15, RPS17, RPL26L1, RPL39, RPL10, RPL36A−HNRNPH2, RPL13A, RPL36A, RPL3L.

C

control
heart-loss — RpL26 KD
heart-loss — RpL3 KD
normal — RpL13A KD
heart-loss — RpL36A KD
constriction — RpL10 KD
ostia — RpS28b KD

Hand $^{4.2}$-Gal4; R94C02::tdTom x RNAi

D

control

rps17 CRISPR

rps28 CRISPR

rpl39 MO

72 hpf

E

Systolic Area Change (μm^2) — Atrium: Control, rps17 CRISPR *, rps28 CRISPR; Ventricle: Control, rps17 CRISPR *, rps28 CRISPR

Diastolic SA (μm^2) — Atrium: Control, rpl39 MO; Ventricle: Control, rpl39 MO *

Figure 3

Figure 4

Figure 5

A

segment

A2　A3　A4　A5

control

RpS15Aa KD

* No heart *

A'

RpS15Aa KD + yorkie OE

yorkie OE

YAP / TEAD (yorkie/scalloped)

A"

RpS15Aa KD + sd KD

* No heart * *

RpS15Aa KD + yorkie/OE + sd KD

* No heart *

B

% (Flies)

partial heart
no heart
whole heart

****
ns
*
**
**

18　21　18　17　18　12　18　(n)

RpS15Aa KD

yki OE

sd^{RNAi}　*yki OE*

sd^{RNAi}　*sd*^{RNAi}

C

RIBOSOMAL STRESS　**Fly**

Xrp1

yorkie　scalloped

↓ Growth
⬇ Proliferation
　 Differentiation

Figure 6

Figure 7

Supp Figure 1

A

Relative EdU+, ACTN1+ CMs

B

ACTN2, EdU, DAPI

C

Relative EdU+, TAGLN+ Fib

D

TAGLN, EdU, DAPI

Supp Figure 2

Supp. Figure 3

Supp Figure 4

Supp Figure 5